<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Current Gastroenterology Reports via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Current Gastroenterology Reports' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Current+Gastroenterology+Reports&t=Current+Gastroenterology+Reports&s=Search&f=source]]></link>
        <lastBuildDate>Sun, 21 Mar 2010 15:07:52 +0100</lastBuildDate>
        <item>
            <title>Update in Acute Pancreatitis</title>
            <link>http://www.medworm.com/index.php?rid=3386409&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa05jx60876103331%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Acute pancreatitis is a common cause for hospitalization that carries a substantial burden of disease in the United States
 and worldwide. Recent reports have encompassed a wide array of topics including new insights into the acinar cell pH microenvironment,
 signal pathways for acinar cell fate, and the innate immune response. Clinical researchers have reported new methods to assess
 disease severity, innovative techniques for management of local complications, the importance of early recognition of pancreatic
 or extrapancreatic infection, and prevention of disease recurrence. Recent data also suggest that specialized centers may
 be of benefit for the management of severe acute pancreatitis. This review summarizes a number of recent advances in basic
 and clinical sc...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386409</comments>
            <pubDate>Thu, 18 Mar 2010 15:26:16 +0100</pubDate>
            <guid isPermaLink="false">3386409</guid>        </item>
        <item>
            <title>Advanced Imaging of Chronic Pancreatitis</title>
            <link>http://www.medworm.com/index.php?rid=3371714&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fbvp2x844k4464524%2F</link>
            <description>This article
 reviews the recognized findings, advantages, and disadvantages of the various imaging modalities in the management of chronic
 pancreatitis, specifically CT, MRI with or without MRCP and/or S-MRCP, ERCP, and EUS.
 
 
	Content Type Journal ArticleDOI 10.1007/s11894-010-0093-4Authors
		Nabil Elia Choueiri, Saint Louis University Health Sciences Center Division of Gastroenterology and Hepatology 3635 Vista Avenue at Grand Boulevard, 9th Floor Saint Louis MO 63110 USANuman Cem Balci, Saint Louis University Health Sciences Center Department of Radiology St. Louis MO USASamer Alkaade, Saint Louis University Health Sciences Center Division of Gastroenterology and Hepatology 3635 Vista Avenue at Grand Boulevard, 9th Floor Saint Louis MO 63110 USAFrank R. Burton, Saint Louis Universit...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3371714</comments>
            <pubDate>Mon, 15 Mar 2010 18:00:22 +0100</pubDate>
            <guid isPermaLink="false">3371714</guid>        </item>
        <item>
            <title>Pancreatic Disease in Children and Adolescents</title>
            <link>http://www.medworm.com/index.php?rid=3371715&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj40x68n65792v71v%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Many childhood pancreatic disorders are rare, although they can represent significant and potentially severe disease. The
 spectrum of disease is very broad, ranging from the complex and bizarre congenital anomalies to the more typical acquired
 causes (eg, drug-induced pancreatitis or trauma injury). Genetics appears to play a major role in many childhood pancreas
 diseases, unlike adults where alcohol is a major factor. Nevertheless, there are similarities, and most of the disorders discussed
 here can be found in both the pediatric and adult age groups. Some of these disorders may be evolving and may be seen in both
 young and older patients. Newer imaging modalities and therapeutic endoscopy continue to be studied, although their ultimate
 role and utility in childr...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3371715</comments>
            <pubDate>Mon, 15 Mar 2010 18:00:15 +0100</pubDate>
            <guid isPermaLink="false">3371715</guid>        </item>
        <item>
            <title>Distinguishing Pancreatic Cancer from Autoimmune Pancreatitis</title>
            <link>http://www.medworm.com/index.php?rid=3360809&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa521264v10842867%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Both autoimmune pancreatitis (AIP) and pancreatic cancer frequently present with obstructive jaundice. However, AIP is a rare
 disease and its diagnosis carries vastly different therapeutic and prognostic implications compared with that of pancreatic
 cancer. The clinical challenge is to distinguish AIP from pancreatic cancer, because the price of misdiagnosis can be heavy.
 Recently, two strategies for differentiating AIP from pancreatic cancer were published, one from Japan and the other from
 the United States. The Japanese strategy relies on cross-sectional imaging, endoscopic retrograde pancreatogram, and serum
 IgG4. The American strategy uses imaging (CT scan), serology (serum IgG4), and evidence of other organ involvement (on CT
 scan) as the first tier of tests...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360809</comments>
            <pubDate>Thu, 11 Mar 2010 18:26:57 +0100</pubDate>
            <guid isPermaLink="false">3360809</guid>        </item>
        <item>
            <title>Pancreatic Cystic Lesions: When to Watch, When to Operate, and When to Ignore</title>
            <link>http://www.medworm.com/index.php?rid=3360810&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg6j6n7064144254r%2F</link>
            <description>This article reviews current guidelines for the evaluation of pancreatic cystic
 lesions, underscores the challenges posed by these lesions, and discusses current and future studies that will aid in patient
 management.
 
 
	Content Type Journal ArticleDOI 10.1007/s11894-010-0097-0Authors
		Brian G. Turner, Massachusetts General Hospital Gastroenterology Unit, 55 Fruit Street Boston MA 02114 USAWilliam R. Brugge, Massachusetts General Hospital Gastroenterology Unit, 55 Fruit Street Boston MA 02114 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360810</comments>
            <pubDate>Thu, 11 Mar 2010 02:24:27 +0100</pubDate>
            <guid isPermaLink="false">3360810</guid>        </item>
        <item>
            <title>Sphincter of Oddi Dysfunction</title>
            <link>http://www.medworm.com/index.php?rid=3360812&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp06v5556h5w7h145%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Sphincter of Oddi dysfunction (SOD) is a poorly-understood disorder, typically presenting as postcholecystectomy, “biliary-type,”
 right-sided abdominal and/or chest wall pain. Most patients referred to specialist clinics for work-up of presumed SOD do
 not, in fact, have anything wrong with their bile ducts or biliary sphincter mechanisms. A careful history and focused physical
 examination will often identify the true source of the pain syndrome, ranging from chest wall costochondritis and nerve injury
 at surgical trochar sites, to gastroparesis and visceral hypersensitivity (“irritable bowel”). The Rome III classification
 of functional gallbladder and biliary disorders defines SOD as episodic (not daily) pain lasting more than 30&amp;nbsp;min, which is
 disrupt...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360812</comments>
            <pubDate>Thu, 11 Mar 2010 02:24:24 +0100</pubDate>
            <guid isPermaLink="false">3360812</guid>        </item>
        <item>
            <title>What Should Be Done with a Dilated Bile Duct?</title>
            <link>http://www.medworm.com/index.php?rid=3360811&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fyqu43665046q5290%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Current methods for imaging the biliary tree include ultrasound, CT, MRI, endoscopic retrograde cholangiography, and endoscopic
 ultrasound (EUS). Bile duct abnormalities may be identified during evaluation of patient symptoms or laboratory abnormalities,
 or incidentally during imaging for another problem. Biliary dilatation, when identified, may be separated into obstructive
 or nonobstructive causes. Clinical presentation should guide decisions on which, if any, additional investigations are necessary.
 Choledocholithiasis is the most common cause of obstructive dilatation and frequently requires decompression. Nonobstructive
 causes include cystic dilatation, aging, and possibly post-cholecystectomy state. Data are limited regarding the yield of
 further investigati...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360811</comments>
            <pubDate>Thu, 11 Mar 2010 02:24:24 +0100</pubDate>
            <guid isPermaLink="false">3360811</guid>        </item>
        <item>
            <title>Difficult Biliary Cannulation</title>
            <link>http://www.medworm.com/index.php?rid=3360813&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft571r2w10p778t78%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) is the most technically challenging procedure routinely performed by
 endoscopists. ERCP cannulation requires the insertion of a subcentimeter catheter through a tiny orifice at a distance of
 almost a meter from the operator. Only after successful cannulation of the bile duct can the real “business” of ERCP be performed
 (eg, sphincterotomy, stone extraction, stent placement). Selective bile duct cannulation is all the more exacting due to the
 occasional anatomic challenge (eg, postsurgical anatomy, duodenal stricture) or wayward catheter. Serious morbid complications
 can and do occur, even in the hands of the most gifted and facile endoscopists. Although there are some “tricks” to facilitate
 successful c...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360813</comments>
            <pubDate>Wed, 10 Mar 2010 16:20:22 +0100</pubDate>
            <guid isPermaLink="false">3360813</guid>        </item>
        <item>
            <title>Therapeutic Endoscopic Ultrasound for Biliary and Pancreatic Disorders</title>
            <link>http://www.medworm.com/index.php?rid=3328660&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff877x423478ug170%2F</link>
            <description>This article reviews existing data and focuses
 on established and emerging EUS techniques for accessing and draining the bile and pancreatic ducts.
 
 
	Content Type Journal ArticleDOI 10.1007/s11894-010-0090-7Authors
		Michael J. Levy, Mayo Clinic College of Medicine Division of Gastroenterology and Hepatology 200 First Street SW, Charlton 8 Rochester MN 55905 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3328660</comments>
            <pubDate>Tue, 02 Mar 2010 10:08:00 +0100</pubDate>
            <guid isPermaLink="false">3328660</guid>        </item>
        <item>
            <title>Cholestatic Liver Disease in Children</title>
            <link>http://www.medworm.com/index.php?rid=3315573&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg3848470mn581627%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Inherited syndromes of intrahepatic cholestasis and biliary atresia are the most common causes of chronic liver disease and
 the prime indication for liver transplantation in children. Our understanding of the pathogenesis of these diseases has increased
 substantially by the discovery of genetic mutations in children with intrahepatic cholestasis and the findings that inflammatory
 circuits are operative at the time of diagnosis of biliary atresia. Building on this solid foundation, recent studies provide
 new insight into genotype-phenotype relationships and how mutations produce altered bile composition and cholestasis. New
 evidence exists that although liver transplantation is curative for patients with end-stage liver disease owing to cholestasis,
 some patients m...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3315573</comments>
            <pubDate>Thu, 25 Feb 2010 17:58:51 +0100</pubDate>
            <guid isPermaLink="false">3315573</guid>        </item>
        <item>
            <title>Treatment of Hepatitis C in 2011: What Can We Expect?</title>
            <link>http://www.medworm.com/index.php?rid=3313058&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn8230p28153622v0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Treatment for chronic hepatitis C virus (HCV) infection is the combination of a peginterferon and ribavirin. Although a fixed
 duration of treatment (24&amp;nbsp;weeks for patients with genotypes 2 and 3 and 48&amp;nbsp;weeks for patients with all other genotypes) has
 been advocated, the best results are likely to be achieved when the duration of therapy is adjusted based on the time to response.
 According to the principles of response-guided therapy, patients with rapid virologic response have a high rate of sustained
 virologic response (SVR) and a low rate of relapse, and can be treated for 24&amp;nbsp;weeks regardless of genotype. In contrast, patients
 who become HCV RNA undetectable at a slower rate need a longer duration of therapy. Direct-acting antiviral agents are curre...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3313058</comments>
            <pubDate>Thu, 25 Feb 2010 08:02:45 +0100</pubDate>
            <guid isPermaLink="false">3313058</guid>        </item>
        <item>
            <title>Nontriglyceride Hepatic Lipotoxicity: The New Paradigm for the Pathogenesis of NASH</title>
            <link>http://www.medworm.com/index.php?rid=3308626&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu57874076j267261%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Lipid droplet accumulation and oxidant stress, once thought to play essential roles in the pathogenesis of nonalcoholic steatohepatitis
 (NASH), may actually represent parallel epiphenomena. Emerging data now point to nontriglyceride lipotoxicity and complex
 mechanisms of hepatocyte injury and apoptosis as the major contributors to the disease phenotype currently recognized as NASH.
 Although specific mediators of hepatic lipotoxicity have not been identified with certainty, abundant evidence from animal
 studies and recent data in humans indicate that free fatty acids in the liver can serve as substrates for formation of nontriglyceride
 lipotoxic metabolites that cause liver injury. The accumulation of triglyceride in droplets may actually be protective, and
 thus th...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308626</comments>
            <pubDate>Wed, 24 Feb 2010 06:55:54 +0100</pubDate>
            <guid isPermaLink="false">3308626</guid>        </item>
        <item>
            <title>Viral Resistance in Hepatitis B: Prevalence and Management</title>
            <link>http://www.medworm.com/index.php?rid=3247959&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp35744543m64k553%2F</link>
            <description>This article focuses on the common natural variants and
 those secondary to nucleos(t)ide therapy, as well as diagnostic methods to detect resistance.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0088-1Authors
		Fred Poordad, Cedars-Sinai Medical Center David Geffen School of Medicine at UCLA, Hepatology and Liver Transplantation 8635 West Third Street, Suite 1060 Los Angeles CA 90048 USAGrace M. Chee, Cedars-Sinai Medical Center Hepatology and Liver Transplantation 8635 West Third Street, Suite 1060 Los Angeles CA 90048 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3247959</comments>
            <pubDate>Fri, 05 Feb 2010 18:19:33 +0100</pubDate>
            <guid isPermaLink="false">3247959</guid>        </item>
        <item>
            <title>Genetic Testing for Wilson Disease: Availability and Utility</title>
            <link>http://www.medworm.com/index.php?rid=3241327&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj218685686332l15%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Wilson disease, a genetic disorder of copper metabolism, presents typically in the second and third decades of life with hepatic
 or neuropsychiatric disease. Clinical presentations often vary depending on age and degree of onset; although clinical and
 biochemical testing can usually establish a diagnosis, the data are difficult to interpret in some patients. Correctly identifying
 patients from nonaffected carriers is important because treatment is lifelong. Genetic testing has greatly improved the ability
 to diagnose Wilson disease in affected patients and in their siblings even without clear-cut clinical and biochemical data.
 Direct sequencing of ATP7B for disease-specific mutations is now the standard for molecular diagnosis. However, haplotype analysis is useful...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3241327</comments>
            <pubDate>Tue, 02 Feb 2010 18:32:07 +0100</pubDate>
            <guid isPermaLink="false">3241327</guid>        </item>
        <item>
            <title>Latest and Emerging Therapies for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis</title>
            <link>http://www.medworm.com/index.php?rid=3224054&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx02r8g651648k253%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the two most common causes of chronic cholestatic
 liver disease in adults. In PBC, therapy with ursodeoxycholic acid (UDCA) is safe and has been associated with tangible biochemical,
 histologic, and survival benefits. However, a need for different or adjuvant therapies remains for specific subsets of PBC
 patients, including those who do not respond to UDCA and those who have advanced histologic disease at presentation. Similarly,
 beneficial therapies for disease-related symptoms that do not typically respond to UDCA (eg, fatigue and pruritus) are still
 needed. In contrast to PBC, no medical therapy of proven benefit has been identified for patients with PSC. In PBC and PSC,
 adequate manag...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224054</comments>
            <pubDate>Thu, 28 Jan 2010 18:05:15 +0100</pubDate>
            <guid isPermaLink="false">3224054</guid>        </item>
        <item>
            <title>Cryptogenic Cirrhosis: What Are We Missing?</title>
            <link>http://www.medworm.com/index.php?rid=3224056&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr55m4p552kr10023%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cryptogenic cirrhosis remains a common clinical condition although recent advances have allowed for a better understanding
 of underlying conditions and associations. The evolving terminology applied to this condition has resulted in some confusion
 and persistent variation among pathologists and clinicians. Typical patients are middle aged with only minor liver enzyme
 abnormalities. Presentations range from incidentally discovered cirrhosis to complications of advanced portal hypertension
 and hepatocellular cancer. Clinicopathologic analysis of these patients indicates that the leading causes include previously
 unrecognized nonalcoholic steatohepatitis, silent autoimmune hepatitis, non-B, non-C viral hepatitis, and occult past ethanol
 exposure. In this article, we ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224056</comments>
            <pubDate>Wed, 27 Jan 2010 20:01:28 +0100</pubDate>
            <guid isPermaLink="false">3224056</guid>        </item>
        <item>
            <title>Antifibrotic Therapies: Will We Ever Get There?</title>
            <link>http://www.medworm.com/index.php?rid=3224055&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F25g827154j696057%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Progressive hepatic fibrosis is the final common pathway for most chronic liver injuries, leading to cirrhosis with risk of
 liver failure and hepatocellular carcinoma. It is now recognized that fibrosis is a dynamic process, and may be reversible
 prior to the establishment of advanced architectural changes to the liver. The most effective antifibrotic strategy is to
 cure the underlying disease process before advanced fibrosis has developed. Unfortunately, this is often not possible, and
 specific antifibrotic therapies are needed. Advances in the understanding of the pathogenesis of liver fibrosis have identified
 several potential novel therapeutic targets, but unfortunately clinical development has been disappointing. One major limitation
 has been the often prolon...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224055</comments>
            <pubDate>Wed, 27 Jan 2010 20:01:28 +0100</pubDate>
            <guid isPermaLink="false">3224055</guid>        </item>
        <item>
            <title>The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers</title>
            <link>http://www.medworm.com/index.php?rid=3224057&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9135jg5504w27q00%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The Baby Boomer generation is composed of 78 million Americans who are just beginning to reach their retirement years. Most
 Boomers have at least one chronic health problem, and these significantly increase the expense of providing medical care.
 Liver disease is the 12th most common cause of death in the United States, representing a relatively small portion of overall
 healthcare costs compared with cardiovascular disease and malignancy. Nonetheless, hepatitis C and fatty liver disease are
 more common in the Boomers and may play a more dominant role as they age. As a consequence, primary liver cancer is likely
 to become more prevalent. As with most chronic illnesses, prevention rather than disease management is likely to have the
 greatest impact. For those already...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224057</comments>
            <pubDate>Wed, 27 Jan 2010 20:01:27 +0100</pubDate>
            <guid isPermaLink="false">3224057</guid>        </item>
        <item>
            <title>Phenotypic Expression of Hereditary Hemochromatosis: What Have We Learned from the Population Studies?</title>
            <link>http://www.medworm.com/index.php?rid=3214089&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3266470226g81766%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Profound advances in our knowledge of hereditary hemochromatosis (HH) during the past 150&amp;nbsp;years have resulted in two distinct
 “iron ages”: the pre-HFE gene era and the post-HFE gene era. During these periods, family studies, HLA association studies, and ultimately HFE gene studies in various populations informed us of the genotypic prevalence as well as the clinical and biochemical penetrance
 of HH. We learned that HH has a highly variable clinical penetrance in susceptible individuals of Northern European ancestry.
 Further, we now recognize that the natural history of HH is not as discrete as previously believed, because genetic and environmental
 modifiers of disease penetrance are increasingly identified as influencing the clinical expression of HH.
 
	Co...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3214089</comments>
            <pubDate>Tue, 26 Jan 2010 07:07:10 +0100</pubDate>
            <guid isPermaLink="false">3214089</guid>        </item>
        <item>
            <title>Training for a Career in Hepatology: Which Path to Take?</title>
            <link>http://www.medworm.com/index.php?rid=3190952&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F32v7xm8705458162%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hepatology has matured significantly over the past two decades, and most gastroenterologists now believe that it is a distinct
 subspecialty. An unmet public health need exists for professional expertise in the care of patients with liver diseases. However,
 our current training programs are struggling to adequately recruit and train physicians with the appropriate expertise in
 advanced and transplant hepatology. This review briefly summarizes the recent discoveries and developments in clinical hepatology,
 describes the past and current training paradigms, and suggests potential pathways to improve the number and quality of physicians
 trained in advanced and transplant hepatology.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0086-3Authors
		Bruce A. Luxon, G...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190952</comments>
            <pubDate>Mon, 18 Jan 2010 18:25:28 +0100</pubDate>
            <guid isPermaLink="false">3190952</guid>        </item>
        <item>
            <title>Regulation of food intake: The gastric X/A-like endocrine cell in the spotlight</title>
            <link>http://www.medworm.com/index.php?rid=3041437&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk52u383614kw002t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Nutritional status influences hormone secretion from specialized enteroendocrine cells within the gut mucosa. These hormones
 regulate food intake by mediating information to central neurocircuitries in the brainstem and forebrain (eg, hypothalamic
 nuclei). Intestinal enteroendocrine cells were believed to be the main source of gut peptides regulating food intake. However,
 recent evidence highlights a specific endocrine cell within the oxyntic glands of the stomach as an important player in appetite
 control. Acylated ghrelin is the only known orexigenic hormone peripherally produced in gastric X/A-like cells and centrally
 acting to stimulate food intake. Recent advances led to the assumption that des-acylated ghrelin, coreleased with acylated
 ghrelin, is also invol...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041437</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:54 +0100</pubDate>
            <guid isPermaLink="false">3041437</guid>        </item>
        <item>
            <title>Gastric infection by Helicobacter pylori</title>
            <link>http://www.medworm.com/index.php?rid=3041436&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu04j47121401q1g8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 Helicobacter pylori infection causes chronic active gastritis, ulcer disease, and gastric cancer. Current eradication regimens use a proton pump
 inhibitor (PPI) and two antibiotics. Triple therapy now has a success rate less than 80%, below the cutoff for efficacious
 eradication. Antibiotic resistance, inconsistent acid control by PPIs, and poor patient compliance contribute to the failure
 rate. H. pylori is a neutralophile that has developed special acid acclimation mechanisms to colonize its acidic gastric niche. Identifying
 the components of these mechanisms will provide novel bactericidal drug targets. Alternatively, better 24-hour acid control
 would increase the efficacy of antibiotics, leading to dual therapy with improved PPIs and amoxicillin. Studies of a...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041436</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:54 +0100</pubDate>
            <guid isPermaLink="false">3041436</guid>        </item>
        <item>
            <title>Diagnostic advances in inflammatory bowel disease (imaging and laboratory)</title>
            <link>http://www.medworm.com/index.php?rid=3041440&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F214w566466061q14%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Autoimmune and antimicrobial antibodies currently play only an adjunctive role in the diagnosis of inflammatory bowel disease
 (IBD). Their sensitivity and specificity are not high enough to be relied upon alone to secure a diagnosis; however, their
 most promising role seems to be in identifying Crohn’s disease patients at a higher risk of progression to intestinal complications.
 Serum C-reactive protein (CRP) correlates well with other measures of biologic activity but not as well with clinical activity.
 CRP can help predict IBD relapses, and in patients with severely active ulcerative colitis may indicate which patients are
 most likely to progress to colectomy. Similarly, fecal lactoferrin and calprotectin are reasonably accurate and noninvasive
 measures of dis...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041440</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:53 +0100</pubDate>
            <guid isPermaLink="false">3041440</guid>        </item>
        <item>
            <title>Optimizing conventional therapies for inflammatory bowel disease</title>
            <link>http://www.medworm.com/index.php?rid=3041439&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa87k7p53418j02h2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Conventional therapies remain the mainstay of treatment for most patients with inflammatory bowel disease (IBD), with only
 a minority of patients requiring biologic therapies. Recently, attention has focused on optimizing dosing strategies for biologic
 agents; however, of equal importance are recent advances in the optimization of conventional IBD therapies. Newer aminosalicylate
 formulations demonstrate similar efficacy with a reduced pill burden and less frequent dosing, while new corticosteroid preparations
 may retain efficacy with a significantly improved safety profile. The limited indications for antibiotics and probiotics have
 been further refined by recent data, although uncertainties remain. Advances in the understanding of thiopurine metabolism
 continue ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041439</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:53 +0100</pubDate>
            <guid isPermaLink="false">3041439</guid>        </item>
        <item>
            <title>Natural history and complications of IBD</title>
            <link>http://www.medworm.com/index.php?rid=3041438&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj65p136324l7254r%2F</link>
            <description>This article summarizes recent knowledge on factors influencing
 the natural history of IBD, including the impact of treatment. Increased understanding of disease mechanisms is needed as
 a basis for new treatment strategies in the future.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0073-8Authors
		Morten H. Vatn, University of Oslo, Medical Clinic, Oslo University Hospital, Rikshospitalet The Institute of Clinical Epidemiology and Molecular Biology (EpiGen), Faculty Division AHUS 0027 Oslo Norway
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 6 / December, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041438</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:53 +0100</pubDate>
            <guid isPermaLink="false">3041438</guid>        </item>
        <item>
            <title>Gastric acid hypersecretory states: Recent insights and advances</title>
            <link>http://www.medworm.com/index.php?rid=3041441&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh802428627600830%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastric acid hypersecretory states are characterized by basal hypersecretion of gastric acid and historically include disorders
 associated with hypergastrinemia, hyperhistaminemia, and those of unknown etiology. Although gastric acid secretion is infrequently
 measured, it is important to recognize the role of gastric hypersecretion in the symptoms of these disorders because they
 share several features of pathogenesis and treatment. In this article, recent important articles reporting insights into their
 diagnosis, pathogenesis, and treatment are reviewed. Particular attention is paid to Zollinger-Ellison syndrome, because it
 has the most extreme acid hypersecretion of this group of disorders and because numerous recent articles deal with various
 aspects of the dia...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041441</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:52 +0100</pubDate>
            <guid isPermaLink="false">3041441</guid>        </item>
        <item>
            <title>Gastric acid inhibition in the treatment of peptic ulcer hemorrhage</title>
            <link>http://www.medworm.com/index.php?rid=3041443&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg032k79726768u10%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Upper gastrointestinal bleeding from peptic ulcer disease is a common clinical event, resulting in considerable patient morbidity
 and significant health care costs. Inhibiting gastric acid secretion is a key component in improving clinical outcomes, including
 reducing rebleeding, transfusion requirements, and surgery. Raising intragastric pH promotes clot stability and reduces the
 influences of gastric acid and pepsin. Patients with high-risk stigmata for ulcer bleeding (arterial bleeding, nonbleeding
 visible vessels, and adherent clots) benefit significantly from and should receive high-dose intravenous proton pump inhibitors
 (PPIs) after successful endoscopic hemostasis. For patients with low-risk stigmata (flat spots or clean ulcer base), oral
 PPI therapy alone...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041443</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:50 +0100</pubDate>
            <guid isPermaLink="false">3041443</guid>        </item>
        <item>
            <title>Managing the risks of IBD therapy</title>
            <link>http://www.medworm.com/index.php?rid=3041442&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F156203001w72624q%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Successful management of the patient with inflammatory bowel disease (IBD) involves not only the induction and maintenance
 of remission, but also the optimization of the benefit-to-risk equation to achieve the greatest gain in quality of life. These
 risks range from intolerance to prescribed medications to potentially life-threatening sequelae (eg, sepsis) of immune suppression.
 A proper awareness of risk on the part of the physician and education of the patient can lead to early detection and institution
 of an appropriate management plan, including risk management and, optimally, primary prevention (eg, prophylactic vaccination).
 One should take the opportunity regularly to reassess the utility and efficacy of existing therapy, with the provision of
 ineffective t...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041442</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:50 +0100</pubDate>
            <guid isPermaLink="false">3041442</guid>        </item>
        <item>
            <title>Insights into IBD pathogenesis</title>
            <link>http://www.medworm.com/index.php?rid=3041445&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp57p5375p221242g%2F</link>
            <description>This article focuses on the recent advances in understanding of IBD from
 the past year, including advances in genetics and immunobiology.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0072-9Authors
		David Q. ShihStephan R. Targan, Cedars-Sinai Inflammatory Bowel Disease Center 8700 Beverly Boulevard, Suite D4063 Los Angeles CA 90048 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 6 / December, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041445</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:48 +0100</pubDate>
            <guid isPermaLink="false">3041445</guid>        </item>
        <item>
            <title>Gut sensing mechanisms</title>
            <link>http://www.medworm.com/index.php?rid=3041444&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy120l75135438ml4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The mechanisms by which the gut senses and responds to nutrients involve the interplay of multiple complex pathways. In addition
 to regulating digestion and absorption, the pathways stimulated by molecules in the gut lumen mediate gastric motility, food
 intake, and satiety. Furthermore, protective mechanisms are activated as necessary to prevent injury, promote healing, and
 limit intake and absorption of potentially toxic substances. This review provides an update on the current knowledge and recent
 findings related to gastric sensing of nutrients, highlighting recent research and future endeavors in the field.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0068-5Authors
		Arushi deFonsekaJonathan Kaunitz, West Los Angeles VA Medical Center Building 114, Suit...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041444</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:48 +0100</pubDate>
            <guid isPermaLink="false">3041444</guid>        </item>
        <item>
            <title>Do COX-2 inhibitors reduce metachronous cancer development?</title>
            <link>http://www.medworm.com/index.php?rid=3041447&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn7x1534703gl4594%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0066-7Authors
		Joseph R. Pisegna, David Geffen School of Medicine at UCLA Los Angeles USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 6 / December, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041447</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:47 +0100</pubDate>
            <guid isPermaLink="false">3041447</guid>        </item>
        <item>
            <title>Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn’s disease)</title>
            <link>http://www.medworm.com/index.php?rid=3041446&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx5t5967563733395%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The introduction of biologic agents and particularly of anti-tumor necrosis factor antibodies dramatically changed the therapeutic
 algorithm in patients with inflammatory bowel diseases. Although the efficacy of these agents has been demonstrated clearly,
 optimal treatment strategies are debated. Recent trials advocate the introduction of biologic agents at an early stage to
 prevent debilitating complications. However, significant adverse events have led to careful selection of patients who will
 benefit most from long-term treatment with biologic agents. Once on biologic therapy, scheduled maintenance therapy is recommended
 to minimize the risk of loss of response. Nevertheless, treatment adaptation is frequently necessary in patients who lose
 response. Interventi...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041446</comments>
            <pubDate>Sun, 29 Nov 2009 09:36:47 +0100</pubDate>
            <guid isPermaLink="false">3041446</guid>        </item>
        <item>
            <title>Common anorectal disorders: Diagnosis and treatment</title>
            <link>http://www.medworm.com/index.php?rid=2816229&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx26859w2343833t3%2F</link>
            <description>This article provides an update on the evaluation and treatment of common anorectal
 disorders.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0062-yAuthors
		Brian E. Lacy, Dartmouth-Hitchcock Medical Center Division of Gastroenterology and Hepatology Area 4C, 1 Medical Center Drive Lebanon NH 03756 USAKirsten Weiser
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 5 / October, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816229</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:47 +0100</pubDate>
            <guid isPermaLink="false">2816229</guid>        </item>
        <item>
            <title>Inflammatory bowel diseases and management considerations: Fertility and pregnancy</title>
            <link>http://www.medworm.com/index.php?rid=2816230&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn6346p8217234350%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Young women with inflammatory bowel disease (IBD) pose a unique set of challenges. These women and their treating physicians
 must make difficult choices in matters regarding conception, pregnancy, and breastfeeding. This review highlights recent evidence
 and management issues that arise when taking care of women with IBD in terms of fertility, outcomes, and medication safety
 in pregnancy and breastfeeding. Ultimately, treatment must be individualized for each patient based on the available evidence
 and the woman’s preferences.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0059-6Authors
		Maria MoscandrewSunanda Kane, Mayo Clinic College of Medicine Division of Gastroenterology and Hepatology 200 First Street SW Rochester MN 55905 USA
	

	
		Journal Current...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816230</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:46 +0100</pubDate>
            <guid isPermaLink="false">2816230</guid>        </item>
        <item>
            <title>Evolving concepts in Clostridium difficile colitis</title>
            <link>http://www.medworm.com/index.php?rid=2816233&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv750002n53076n40%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 Clostridium difficile infection (CDI) is the most important cause of nosocomial diarrhea. The emergence of a hypervirulent strain and other factors
 including antibiotic overuse contribute to the increasing incidence and severity of this potentially lethal infection. CDI
 has been reported in persons previously considered as low risk, such as young healthy persons without exposure to health care
 settings or antibiotics, peripartum women, and children. In patients with inflammatory bowel disease, the risk of C. difficile infection is even greater, with higher rates of hospitalization, bowel surgery, and mortality. With increasing incidence
 and severity of disease, the need for improved diagnostic, treatment, and infection control strategies cannot be overstated.
 
	C...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816233</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:44 +0100</pubDate>
            <guid isPermaLink="false">2816233</guid>        </item>
        <item>
            <title>Serotonin and the GI tract</title>
            <link>http://www.medworm.com/index.php?rid=2816232&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd2r7w776784g2843%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Serotonin (5-hydroxytryptamine, 5-HT) participates in several functions of the gastrointestinal tract. Receptors in seven
 families (5-HT1-5-HT7) were identified, many of which are present on enterocytes, intrinsic and extrinsic neurons, interstitial cells, and gut
 myocytes. Most 5-HT is released from enterochromaffin cells in response to physiologic and pathologic stimuli. Roles of 5-HT
 in health include control of normal gut motor activity, secretion, and sensation, and regulation of food intake and cell growth.
 Abnormalities of serotonergic function contribute to symptom genesis in functional bowel disorders, inflammatory and infectious
 diseases of the gut, emetic responses to varied stimuli, obesity, and dysregulation of cell growth. Therapies acting as agonists...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816232</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:44 +0100</pubDate>
            <guid isPermaLink="false">2816232</guid>        </item>
        <item>
            <title>NSAIDs and the gastrointestinal tract</title>
            <link>http://www.medworm.com/index.php?rid=2816231&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm482716k16853678%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;NSAIDs incur significant gastrointestinal (GI) side effects. The complication risk increases with history of peptic ulcer
 or older age. Helicobacter pylori infection and cardioprotective aspirin have independent and additive risks in the presence of NSAID use. NSAID enteropathy
 is increasingly recognized. Cardiovascular and GI risk stratification and H. pylori infection testing should be done before initiating NSAIDs. An NSAID combined with a proton pump inhibitor (PPI) is comparable
 to cyclooxygenase (COX)-2 inhibitors for gastroprotection, but for high-risk patients, COX-2 plus PPI should be considered.
 Aspirin and COX-2 inhibitors are associated with reduced colon adenoma risk, but higher dose and longer duration of treatment
 with aspirin appears effective. Henc...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816231</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:44 +0100</pubDate>
            <guid isPermaLink="false">2816231</guid>        </item>
        <item>
            <title>Clinical significance of inflammatory markers</title>
            <link>http://www.medworm.com/index.php?rid=2816234&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F420817135824q117%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Inflammatory markers play a key role in the evaluation of patients with gastrointestinal symptoms. For patients presenting
 with nonspecific symptoms of abdominal pain and diarrhea, distinguishing inflammatory bowel disease from other disorders can
 be difficult, and invasive diagnostic procedures may be required. Inflammatory markers can be useful to differentiate patients
 who may require further workup from those who do not. Several serum, fecal, and other markers are reviewed for their use in
 clinical practice. Although no single ideal marker exists, a few show promise in diagnosing inflammatory disease, monitoring
 disease activity, and predicting relapse.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0055-xAuthors
		Bincy P. Abraham, Baylor College of Med...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816234</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:43 +0100</pubDate>
            <guid isPermaLink="false">2816234</guid>        </item>
        <item>
            <title>Bile acids in regulation of intestinal physiology</title>
            <link>http://www.medworm.com/index.php?rid=2816236&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb364t60126436836%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In addition to their roles in facilitating lipid digestion and absorption, bile acids are recognized as important regulators
 of intestinal function. Exposure to bile acids can dramatically influence intestinal transport and barrier properties; in
 recent years, they have also become appreciated as important factors in regulating cell growth and survival. Indeed, few cells
 reside within the intestinal mucosa that are not altered to some degree by exposure to bile acids. The past decade saw great
 advances in the knowledge of how bile acids exert their actions at the cellular and molecular levels. In this review, we summarize
 the current understanding of the role of bile acids in regulation of intestinal physiology.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816236</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:42 +0100</pubDate>
            <guid isPermaLink="false">2816236</guid>        </item>
        <item>
            <title>Diabetic diarrhea</title>
            <link>http://www.medworm.com/index.php?rid=2816235&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk36528013n5381r4%2F</link>
            <description>This article focuses on the etiologies of diarrhea
 that are seen with higher incidence in diabetic patients.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0054-yAuthors
		Milena GouldJoseph H. Sellin, Baylor College of Medicine Section of Gastroenterology 1709 Dryden Road, Suite 8.36 Houston TX 77030 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 5 / October, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816235</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:42 +0100</pubDate>
            <guid isPermaLink="false">2816235</guid>        </item>
        <item>
            <title>Serrated adenomas</title>
            <link>http://www.medworm.com/index.php?rid=2816238&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj843754567321277%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Serrated adenomas are categorized as sessile serrated adenomas (SSAs) and traditional serrated adenomas (TSAs). SSAs are more
 prevalent in the proximal colon and lack classic dysplasia, whereas TSAs are more prevalent in the rectosigmoid and have cytologic
 dysplasia. Serrated adenomas may progress to colorectal adenocarcinoma through diverse molecular alterations. Colonoscopy
 is the only test for the early detection of serrated adenomas that allows inspection of the entire colon and same-session
 biopsy sampling or polypectomy, if necessary. If an endoscopic biopsy at the right colon reveals SSA without cytologic dysplasia
 or biopsy at the rectosigmoid reveals SSA or TSA, those polyps should be excised or surgically resected as necessary. Postpolypectomy
 surveillan...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816238</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:41 +0100</pubDate>
            <guid isPermaLink="false">2816238</guid>        </item>
        <item>
            <title>Fructose-sorbitol malabsorption</title>
            <link>http://www.medworm.com/index.php?rid=2816237&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft18g5qv48262u572%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Important dietary carbohydrates such as fructose and sorbitol are incompletely absorbed in the normal small intestine. This
 malabsorption is sometimes associated with abdominal complaints and diarrhea development, symptoms indistinguishable from
 those of functional bowel disease. Recently, polymerized forms of fructose (fructans) also were implicated in symptom production
 in patients with irritable bowel syndrome (IBS). Evidence from uncontrolled and controlled challenge studies suggests that
 malabsorbed sugars (fructose, sorbitol, lactose) and fructans may act as dietary triggers for clinical symptoms suggestive
 of IBS. Further placebo-controlled studies are needed to obtain definite conclusions about the role of dietary sugar malabsorption
 in functional bowel di...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816237</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:41 +0100</pubDate>
            <guid isPermaLink="false">2816237</guid>        </item>
        <item>
            <title>Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding</title>
            <link>http://www.medworm.com/index.php?rid=2816239&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F234l330745584013%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0065-8Authors
		Alan B. R. Thomson, University of Alberta Division of General Internal Medicine, Department of Medicine Edmonton Canada
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 5 / October, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816239</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:39 +0100</pubDate>
            <guid isPermaLink="false">2816239</guid>        </item>
        <item>
            <title>Advances in colorectal cancer screening</title>
            <link>http://www.medworm.com/index.php?rid=2816240&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1x4r55854m25833r%2F</link>
            <description>This article provides a focused
 assessment of effectiveness, limitations, and alternative available screening methods. New modalities endorsed in the updated
 guidelines (eg, fecal immunochemical tests, fecal DNA, and CT colonography) are reviewed. In addition, advances and updates
 in existing tests (eg, guaiac-based fecal occult blood tests and colonoscopy) are evaluated.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0061-zAuthors
		Hongha T. VuCarol A. Burke, Cleveland Clinic Foundation Digestive Disease Institute, Department of Gastroenterology and Hepatology 9500 Euclid Avenue, A-30 Cleveland OH 44195 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 5 / October, 2009 (...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816240</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:38 +0100</pubDate>
            <guid isPermaLink="false">2816240</guid>        </item>
        <item>
            <title>Food for thought</title>
            <link>http://www.medworm.com/index.php?rid=2816241&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq3h43h86u5427016%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0064-9Authors
		Joseph H. Sellin, Baylor College of Medicine Division of Gastroenterology Houston USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 5 / October, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816241</comments>
            <pubDate>Sun, 20 Sep 2009 05:37:37 +0100</pubDate>
            <guid isPermaLink="false">2816241</guid>        </item>
        <item>
            <title>A role for corticotropin-releasing factor in functional gastrointestinal disorders</title>
            <link>http://www.medworm.com/index.php?rid=2638923&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7768234387x23g26%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Functional gastrointestinal disorders (FGIDs), which include irritable bowel syndrome (IBS), encompass a heterogeneous group
 of diseases identified by chronic or recurrent symptom-based diagnostic criteria. Psychosocial factors are key components
 in the outcome of clinical manifestations of IBS symptoms. Anxiogenic and endocrine responses to stress are mediated by the
 corticotropin-releasing factor (CRF)-CRF1 receptor pathway. Preclinical studies show that activation of the CRF1 receptor by exogenous CRF or stress recapitulates many functional symptoms of IBS diarrhea-predominant patients as related
 to anxiogenic/hypervigilant behavior, autonomic nervous system alterations, induction of diarrhea, visceral hyperalgesia,
 enhanced colonic motility, mucus secretion, in...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638923</comments>
            <pubDate>Wed, 22 Jul 2009 02:35:07 +0100</pubDate>
            <guid isPermaLink="false">2638923</guid>        </item>
        <item>
            <title>Is rosacea another disorder of gut microbes?</title>
            <link>http://www.medworm.com/index.php?rid=2638924&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe648601k380m123m%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0049-8Authors
		Walter J. Coyle, Division of Gastroenterology and Hepatology LaJolla USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 4 / August, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638924</comments>
            <pubDate>Wed, 22 Jul 2009 02:35:06 +0100</pubDate>
            <guid isPermaLink="false">2638924</guid>        </item>
        <item>
            <title>Controversial results with use of probiotics in critical illness: Confirmation of early positive results</title>
            <link>http://www.medworm.com/index.php?rid=2638925&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc5t8rl27921442q3%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0051-1Authors
		Jeremy R. Stapleton, University of Louisville School of Medicine Division of Gastroenterology/Hepatology Louisville USAStephen A. McClave, University of Louisville School of Medicine Louisville USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 4 / August, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638925</comments>
            <pubDate>Wed, 22 Jul 2009 02:35:03 +0100</pubDate>
            <guid isPermaLink="false">2638925</guid>        </item>
        <item>
            <title>Controversial results with use of probiotics in critical illness: Contradictory findings from large multicenter trial</title>
            <link>http://www.medworm.com/index.php?rid=2638926&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb042hw8413248520%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0052-0Authors
		Jeremy R. Stapleton, University of Louisville School of Medicine Division of Gastroenterology/Hepatology Louisville USAStephen A. McClave, University of Louisville School of Medicine Louisville USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 4 / August, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638926</comments>
            <pubDate>Wed, 22 Jul 2009 02:35:02 +0100</pubDate>
            <guid isPermaLink="false">2638926</guid>        </item>
        <item>
            <title>Controversial results with use of probiotics in critical illness: Early single-center positive results</title>
            <link>http://www.medworm.com/index.php?rid=2638927&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj52g274816876782%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0050-2Authors
		Jeremy R. Stapleton, University of Louisville School of Medicine Division of Gastroenterology/Hepatology Louisville USAStephen A. McClave, University of Louisville School of Medicine Louisville USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 4 / August, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638927</comments>
            <pubDate>Wed, 22 Jul 2009 02:35:01 +0100</pubDate>
            <guid isPermaLink="false">2638927</guid>        </item>
        <item>
            <title>Nutrition support therapy in acute kidney injury: Distinguishing dogma from good practice</title>
            <link>http://www.medworm.com/index.php?rid=2638929&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff72608776r837500%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Acute kidney injury (AKI) is a frequently observed complication in critically ill patients. Its presentation may range from
 the early risk of renal dysfunction to complete renal failure. Morbidity and mortality in the AKI patient increase with the
 decline of renal function. Appropriate nutrition therapy is essential in the medical management of the AKI patient. Assessment
 of nutritional requirements should take into account the patient’s underlying complication, comorbid medical conditions, and
 severity of the renal dysfunction. Various stages of AKI determine the direction of nutrition therapy. Additionally, understanding
 the macro- and micronutrient modifications and electrolyte and vitamin alterations that should be implemented are vital for
 better patient ou...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638929</comments>
            <pubDate>Wed, 22 Jul 2009 02:34:50 +0100</pubDate>
            <guid isPermaLink="false">2638929</guid>        </item>
        <item>
            <title>The microbiome and obesity: Is obesity linked to our gut flora?</title>
            <link>http://www.medworm.com/index.php?rid=2638928&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff478905k8606g5m4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The human gut is a lush microbial ecosystem containing about 100 trillion microorganisms, whose collective genome, the microbiome,
 contains 100-fold more genes than the entire human genome. The symbiosis of our extended genome plays a role in host homeostasis
 and energy extraction from diet. In this article, we summarize some of the studies that have advanced the understanding of
 the microbiome and its effects on metabolism, obesity, and health. Metagenomic studies demonstrated that certain mixes of
 gut microbiota may protect or predispose the host to obesity. Furthermore, microbiota transplantation studies in germ-free
 murine models showed that the efficient energy extraction traits of obese-type gut flora are transmissible. The proposed methods
 by which the micr...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638928</comments>
            <pubDate>Wed, 22 Jul 2009 02:34:50 +0100</pubDate>
            <guid isPermaLink="false">2638928</guid>        </item>
        <item>
            <title>Treating pelvic floor disorders of defecation: Management or cure?</title>
            <link>http://www.medworm.com/index.php?rid=2638930&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx1642183n6t24507%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pelvic floor disorders that affect defecation consist of structural disorders (eg, rectocele) and functional disorders (eg,
 dyssynergic defecation). Evaluation includes a thorough history and physical examination, a careful digital rectal examination,
 and physiologic tests such as anorectal manometry, colonic transit study, and balloon expulsion test. Defecography and dynamic
 MRI may facilitate detection of structural defects. Management consists of education and counseling regarding bowel function,
 diet, laxatives, and behavioral therapies. Recently, several randomized, clinical trials have shown that biofeedback therapy
 is effective in dyssynergic defecation. Dyssynergia may also coexist in structural disorders such as solitary rectal ulcer
 syndrome or rectocele...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638930</comments>
            <pubDate>Wed, 22 Jul 2009 02:34:45 +0100</pubDate>
            <guid isPermaLink="false">2638930</guid>        </item>
        <item>
            <title>Managing dyspepsia</title>
            <link>http://www.medworm.com/index.php?rid=2638931&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn2q381125029h77l%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The prevalence of dyspepsia in the general population is as high as 40%, and its management represents a considerable financial
 burden to the health care system. Causes of dyspepsia amenable to medical therapy include peptic ulcer and functional dyspepsia,
 and testing for Helicobacter pylori and treating positive individuals is beneficial in both conditions. Individuals presenting for the first time with uninvestigated
 dyspepsia, age greater than 50 years, or alarm features require upper gastrointestinal (GI) endoscopy to exclude gastroesophageal
 malignancy. Upper GI endoscopy for younger individuals without alarm features is not cost-effective compared with the “test
 and treat” approach. Test and treat and empirical acid-suppression using a proton pump inhibit...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638931</comments>
            <pubDate>Wed, 22 Jul 2009 02:34:44 +0100</pubDate>
            <guid isPermaLink="false">2638931</guid>        </item>
        <item>
            <title>Escherichia coli O157: What every internist and gastroenterologist should know</title>
            <link>http://www.medworm.com/index.php?rid=2638932&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6178378251v4171v%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Infections with Escherichia coli O157:H7 have gained media attention in recent years because of cases associated with unusual sources (eg, produce and swimming
 pools). Although most adults recover without sequelae, children and the elderly are more likely to develop complications (eg,
 hemolytic uremic syndrome and death). The diagnosis typically has been made by culture; however, newer handheld immunoassays
 and polymerase chain reaction technology have led to more rapid detection of this important pathogen in stools, food, and
 water. Treatment is largely supportive; nonetheless, new methods to neutralize or bind toxin, such as probiotics, monoclonal
 antibodies, and recombinant bacteria, are showing promise to treat patients infected with E. coli O157:H7. The role o...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638932</comments>
            <pubDate>Wed, 22 Jul 2009 02:34:41 +0100</pubDate>
            <guid isPermaLink="false">2638932</guid>        </item>
        <item>
            <title>The burden of IBS: Looking at metrics</title>
            <link>http://www.medworm.com/index.php?rid=2638933&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm27x325767j3k244%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Irritable bowel syndrome (IBS) is a prevalent and expensive condition that significantly impairs health-related quality of
 life (HRQOL) and reduces work productivity. Based on strict criteria, 7% to 10% of people have IBS worldwide. Community-based
 data indicate that IBS-diarrhea and IBS-mixed subtypes are more prevalent than IBS-constipation, and that patients may switch
 among subtype groups. IBS is 1.5 times more common in women than in men, more common in lower socioeconomic groups, and more
 commonly diagnosed in patients younger than 50 years of age. Patients with IBS visit the doctor more frequently, use more
 diagnostic tests, consume more medications, miss more workdays, have lower work productivity, are hospitalized more frequently,
 and consume more overall...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638933</comments>
            <pubDate>Wed, 22 Jul 2009 02:34:39 +0100</pubDate>
            <guid isPermaLink="false">2638933</guid>        </item>
        <item>
            <title>Prophylaxis for travelers’ diarrhea</title>
            <link>http://www.medworm.com/index.php?rid=2638934&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F513571716201ml00%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Travelers’ diarrhea affects more than 10 million people per year and is usually contracted through the ingestion of microbially
 contaminated food or water. Although most cases resolve in 3 to 5 days, chronic conditions are associated with acute infections.
 Prevention encompasses avoidance of ingesting contaminated products and, in certain situations, taking prophylactic medications.
 The available prophylactic antibiotics are very effective in prevention, but are recommended only for specific at-risk individuals
 and are contraindicated for most travelers.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0043-1Authors
		Emily Singh, Scripps Clinic 10666 North Torrey Pines Road La Jolla CA 92037 USADavid Redfield
	

	
		Journal Current Gastroenterology ReportsOn...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638934</comments>
            <pubDate>Wed, 22 Jul 2009 02:34:38 +0100</pubDate>
            <guid isPermaLink="false">2638934</guid>        </item>
        <item>
            <title>Hepatotoxic herbs: Will injury mechanisms guide treatment strategies?</title>
            <link>http://www.medworm.com/index.php?rid=2638935&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl69k11tx720g508n%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Harmful and fatal outcomes related to specific herbal therapies are reported with increasing regularity. However, US physicians
 remain inadequately informed about potential toxicities. The purpose of this focused review is to highlight past and more
 recently recognized herbal therapies or complementary and alternative medicine (CAM) that are shown to cause hepatotoxicity.
 Where available, the proposed mechanisms for toxicity are discussed. An aggressive approach for more stringent regulation
 of CAM is needed, in addition to a systematic and scientific study of causality and underlying toxic mechanisms, to provide
 reliable information about the safety of CAM and enable practitioners to deliver effective remedies when toxicities occur.
 
	Content Type Journal Article...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638935</comments>
            <pubDate>Wed, 22 Jul 2009 02:34:37 +0100</pubDate>
            <guid isPermaLink="false">2638935</guid>        </item>
        <item>
            <title>Should the principle of “pay for performance” be applied to nutrition support?</title>
            <link>http://www.medworm.com/index.php?rid=2638936&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F46473mk521434156%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Americans spent 2.4 trillion dollars on health care in 2008. The massive size of this expenditure has led to perpetual efforts
 to improve health care quality while attempting to reduce overall cost. A recent development in reimbursement strategies is
 the “pay-for-performance” model. Retrospective reports showed variable success for this model for the treatment of acute myocardial
 infarction, pneumonia, and congestive heart failure. As the model gains popularity, there is pressure to apply pay for performance
 to an increasing number of diseases and treatment settings. In this article, we evaluate the appropriateness of the pay-for-performance
 model with regard to nutritional support in the hospitalized patient.
 
	Content Type Journal ArticleDOI 10.1007/s11894-0...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638936</comments>
            <pubDate>Wed, 22 Jul 2009 02:34:35 +0100</pubDate>
            <guid isPermaLink="false">2638936</guid>        </item>
        <item>
            <title>Outcomes in pediatric autoimmune hepatitis</title>
            <link>http://www.medworm.com/index.php?rid=2429598&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh3p1t71583h286g0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Autoimmune hepatitis (AIH) is a common cause of acute and chronic hepatitis in childhood. Once the diagnosis is established,
 treatment with corticosteroid or corticosteroid and azathioprine is indicated. Most children with AIH respond to such therapy
 and experience remission from active disease. Eliminating drug therapy while maintaining remission is the ultimate goal of
 therapy. The optimal duration of therapy before drug elimination is unclear. Relapse rate is inversely related to therapy
 duration before drug withdrawal; thus, discontinuing immunosuppressive treatment is considered only after at least 1 to 2
 years of complete remission. When applying a slow and systematic approach, many children with AIH can successfully be weaned
 off immunosuppression completel...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429598</comments>
            <pubDate>Thu, 21 May 2009 06:02:48 +0100</pubDate>
            <guid isPermaLink="false">2429598</guid>        </item>
        <item>
            <title>Evaluation of esophageal motor disorders in the era of high-resolution manometry and intraluminal impedance</title>
            <link>http://www.medworm.com/index.php?rid=2429600&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg8714166917m563k%2F</link>
            <description>This article provides an update on these technologies
 in clinical practice and how they may be helpful in the future.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0029-zAuthors
		John E. Pandolfino, Northwestern University, Feinberg School of Medicine Division of Gastroenterology, Department of Medicine 676 North St. Clair Street, Suite 1400 Chicago IL 60611 USAWilliam J. Bulsiewicz
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 3 / June, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429600</comments>
            <pubDate>Thu, 21 May 2009 06:02:47 +0100</pubDate>
            <guid isPermaLink="false">2429600</guid>        </item>
        <item>
            <title>Dilated intercellular spaces as a marker of GERD</title>
            <link>http://www.medworm.com/index.php?rid=2429599&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F18571451424416l0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastroesophageal reflux disease (GERD) is typically heralded by the substernal burning pain of heartburn. On endoscopic examination,
 about one third of GERD subjects with heartburn have erosive disease, and the remainder have nonerosive reflux disease (NERD).
 Unlike patients with erosive disease, those with NERD (∼ 50%) often do not respond to therapy with proton pump inhibitors
 (PPIs), raising the question of whether they have NERD and, if they do, whether the cause of their symptoms is similar to
 those who respond to PPIs. Recently, biopsies established that subjects with heartburn and PPI-responsive NERD, like those
 with erosive esophagitis, have lesions within the esophageal epithelium known as dilated intercellular space (DIS). In this
 article, we discuss t...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429599</comments>
            <pubDate>Thu, 21 May 2009 06:02:47 +0100</pubDate>
            <guid isPermaLink="false">2429599</guid>        </item>
        <item>
            <title>Eosinophilic esophagitis: Concepts, controversies, and evidence</title>
            <link>http://www.medworm.com/index.php?rid=2429602&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8007041q71447g1t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Eosinophilic esophagitis has become a prominent chronic esophageal disorder in clinical pediatric and adult gastroenterology.
 Its manifestations are protean in childhood, but dysphagia predominates the clinical presentation in adults. Adverse immune
 responsiveness to dietary antigens underlies most cases, as is reflected in clinical and histologic remission with appropriate
 diet management in the majority, although an understanding of the mechanisms underlying the inflammatory process remains incomplete.
 Intense investigations to explain the underpinnings of the disorder and to discover effective therapy are ongoing.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0034-2Authors
		Philip E. Putnam, University of Cincinnati College of Medicine, Cincinnati Childr...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429602</comments>
            <pubDate>Thu, 21 May 2009 06:02:46 +0100</pubDate>
            <guid isPermaLink="false">2429602</guid>        </item>
        <item>
            <title>Esophageal, gastric, and duodenal manifestations of IBD and the role of upper endoscopy in IBD diagnosis</title>
            <link>http://www.medworm.com/index.php?rid=2429601&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F049p4782v234n551%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Upper gastrointestinal (GI) tract inflammation in inflammatory bowel disease has become increasingly recognized, even in the
 absence of specific localizing symptoms, as patients more frequently undergo upper endoscopy. Although the recent Montreal
 classification system allowed classification of upper GI involvement in Crohn’s disease (CD), independent of other locations,
 a consensus regarding the definition of what qualifies as significant “involvement” is still lacking. Reported incidence data
 vary considerably depending on the definitions used and the selected target population. Pediatric data suggest that upper
 endoscopy is useful in differentiating CD from ulcerative colitis, when inflammation is otherwise predominantly confined to
 the colon; however, th...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429601</comments>
            <pubDate>Thu, 21 May 2009 06:02:46 +0100</pubDate>
            <guid isPermaLink="false">2429601</guid>        </item>
        <item>
            <title>Pediatric juvenile polyposis syndromes: An update</title>
            <link>http://www.medworm.com/index.php?rid=2429604&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx2r43525wt526135%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Colon polyps are a common finding in pediatrics and can present with rectal bleeding, abdominal pain, or polyp prolapse from
 the rectum. Histologically classified as hamartomas, these isolated pediatric polyps lack epithelial dysplasia and have no
 cancer risk. However, when polyps are present in greater numbers, or are associated with a family history of polyps or colon
 or other cancers, a polyposis or hereditary colorectal cancer syndrome should be considered. Using a casebased format, this
 article reviews the clinical features and provides updates on the three most common hamartomatous polyp syndromes of childhood:
 juvenile polyposis syndrome, Peutz-Jeghers syndrome, and the PTEN hamartoma tumor syndrome. Each syndrome has distinctive
 intestinal and extra-intest...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429604</comments>
            <pubDate>Thu, 21 May 2009 06:02:45 +0100</pubDate>
            <guid isPermaLink="false">2429604</guid>        </item>
        <item>
            <title>Probiotics in pediatric inflammatory bowel diseases</title>
            <link>http://www.medworm.com/index.php?rid=2429603&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff311x14j021l7m24%2F</link>
            <description>This article examines the
 currently available published trials studying probiotics for the treatment of IBD, with particular emphasis on their role
 in pediatric IBD patients.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0037-zAuthors
		Ajay S. Gulati, University of North Carolina at Chapel Hill Department of Pediatrics, Division of Pediatric Gastroenterology 130 Mason Farm Road, 5143 Bioinformatics, CB-7229 Chapel Hill NC 27599 USAMarla C. Dubinsky
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 3 / June, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429603</comments>
            <pubDate>Thu, 21 May 2009 06:02:45 +0100</pubDate>
            <guid isPermaLink="false">2429603</guid>        </item>
        <item>
            <title>Eosinophilic esophagitis: Pathophysiology and optimal management</title>
            <link>http://www.medworm.com/index.php?rid=2429605&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnl786g935hkn83k8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Eosinophilic esophagitis (EoE) is an increasingly recognized disease characterized by esophageal symptoms accompanied by increased
 esophageal mucosal eosinophilia. The reasons for the increasing prevalence and understanding of the pathogenesis of EoE are
 areas of active investigation. Food and environmental allergy, host immunologic predisposition, and interactions with gastroesophageal
 reflux disease have emerged as important aspects of the disease. The optimal management of EoE is controversial and evolving.
 Therapeutic options include medical therapy with acid suppression, corticosteroids, and biologic agents. Elimination diets
 and endoscopic esophageal dilation have shown effectiveness. Management strategies for individual patients range from clinical
 observat...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429605</comments>
            <pubDate>Thu, 21 May 2009 06:02:44 +0100</pubDate>
            <guid isPermaLink="false">2429605</guid>        </item>
        <item>
            <title>Current perspectives on pediatric intestinal transplantation</title>
            <link>http://www.medworm.com/index.php?rid=2429607&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F520075l114506042%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Irreversible intestinal failure in children is predominantly caused by surgical conditions such as volvulus, necrotizing enterocolitis,
 and gastroschisis. Functional intestinal failure from motility disorders such as intestinal pseudo-obstruction or enterocyte
 dysfunction with microvillus inclusion disease also may require intestine replacement. Approved indications for intestinal
 transplantation include liver dysfunction, loss of major venous access, frequent central line-related sepsis, and recurrent
 episodes of severe dehydration despite intravenous fluid management. Surgical options include transplantation of the isolated
 intestine, combined liver-intestine transplantation, or multivisceral transplantation of the stomach, duodenum, pancreas,
 and small bowel (w...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429607</comments>
            <pubDate>Thu, 21 May 2009 06:02:42 +0100</pubDate>
            <guid isPermaLink="false">2429607</guid>        </item>
        <item>
            <title>Screening and surveillance of Barrett’s esophagus</title>
            <link>http://www.medworm.com/index.php?rid=2429606&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw5007753qn204236%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Esophageal adenocarcinoma (EAC) is the most rapidly increasing cancer in the Western world and Barrett’s esophagus (BE) is
 the only known precursor lesion for this lethal cancer. Long-term survival may be improved if EAC is diagnosed early, providing
 an opportunity for early intervention. Screening for BE in patients with gastroesophageal reflux disease is not routinely
 recommended; however, if diagnosed, enrollment into a surveillance program may be beneficial. Surveillance of all patients
 with known BE is probably not costeffective and factors predictive of BE progression to dysplasia/EAC are poorly understood.
 Screening and surveillance examinations are also faced with challenges in the endoscopic detection of intestinal metaplasia
 and dysplasia. Future appli...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429606</comments>
            <pubDate>Thu, 21 May 2009 06:02:42 +0100</pubDate>
            <guid isPermaLink="false">2429606</guid>        </item>
        <item>
            <title>Second-line therapy for severe pediatric ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2429610&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F45m406n0378441u8%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0026-2Authors
		Susan R. Orenstein
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 3 / June, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429610</comments>
            <pubDate>Thu, 21 May 2009 06:02:41 +0100</pubDate>
            <guid isPermaLink="false">2429610</guid>        </item>
        <item>
            <title>The clinical usefulness of high-resolution manometry for the management of achalasia</title>
            <link>http://www.medworm.com/index.php?rid=2429609&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F466170g210447734%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0027-1Authors
		Marcelo F. Vela
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 3 / June, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429609</comments>
            <pubDate>Thu, 21 May 2009 06:02:41 +0100</pubDate>
            <guid isPermaLink="false">2429609</guid>        </item>
        <item>
            <title>The relationship between gastroesophageal reflux disease and sleep</title>
            <link>http://www.medworm.com/index.php?rid=2429608&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl5819431031737h6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recent studies demonstrate a bidirectional relationship between gastroesophageal reflux disease (GERD) and sleep in which
 nighttime reflux leads to sleep deprivation and sleep deprivation can exacerbate GERD by enhancing perception of intraesophageal
 stimuli. Current treatment primarily focuses on reducing nighttime reflux, thus improving sleep quality. Future studies are
 needed to further explore the relationship between GERD and sleep and the potential of novel therapeutic options to interrupt
 the vicious cycle between them.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0032-4Authors
		Ronnie Fass, Southern Arizona VA Health Care System GI Section (1-111-GI) 3601 South Sixth Avenue Tucson AZ 85723 USA
	

	
		Journal Current Gastroenterology ReportsOnline I...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2429608</comments>
            <pubDate>Thu, 21 May 2009 06:02:41 +0100</pubDate>
            <guid isPermaLink="false">2429608</guid>        </item>
        <item>
            <title>Laparoscopic pancreatic surgery: What now and what next?</title>
            <link>http://www.medworm.com/index.php?rid=2277383&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fbq47670w40487471%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In recent years, improved laparoscopic skill sets have expanded surgical management of pancreatic disease to encompass pancreatic
 resection, tumor enucleation, débridement, and drainage. With the aid of radio-logically guided drainage catheters, necrosectomy
 for acute pancreatitis can be delayed and accomplished laparoscopically in a select patient population. Pancreatic pseudocysts
 from chronic pancreatitis can now be approached via minimally invasive strategies, including emerging combined laparoendoscopic
 procedures and natural orifice transluminal endoscopic surgery. It is clear that laparoscopic pancreaticoduodenectomy is possible
 in experienced hands; pancreatic neoplasms in the body and tail are more suitable for laparoscopic procedures because distal
 panc...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277383</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:23 +0100</pubDate>
            <guid isPermaLink="false">2277383</guid>        </item>
        <item>
            <title>Neuroendocrine tumors of the pancreas</title>
            <link>http://www.medworm.com/index.php?rid=2277384&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fjt335h50028r3h46%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pancreatic endocrine tumors are rare neoplasms accounting for less than 5% of pancreatic malignancies. They are broadly classified
 into either functioning tumors (insulinomas, gastrinomas, glucagonomas, VIPomas, and somatostatinomas) or nonfunctioning tumors.
 The diagnosis of these tumors is difficult and requires a careful history and examination combined with laboratory tests and
 radiologic imaging. Signs and symptoms are usually related to hormone hypersecretion in the case of functioning tumors and
 to tumor size or metastases with nonfunctioning tumors. Surgical resection remains the treatment of choice even in the face
 of metastatic disease. Further development of novel diagnostic and treatment modalities offers potential to greatly improve
 quality of life an...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277384</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:22 +0100</pubDate>
            <guid isPermaLink="false">2277384</guid>        </item>
        <item>
            <title>Prevention, detection, and management of infected necrosis in severe acute pancreatitis</title>
            <link>http://www.medworm.com/index.php?rid=2277385&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr4npr52q44301102%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The management of infected peripancreatic or pancreatic necrosis in patients with severe pancreatitis has changed considerably
 in recent years. This review discusses the recent literature on prevention, detection, and management of infected necrosis.
 Though antibiotics, probiotics, and enteral nutrition have been tried to prevent infected necrosis, only enteral nutrition
 has consistently proven to be effective. Antibiotics and probiotics have not shown a consistent beneficial effect on outcome.
 Enteral nutrition reduced infectious complications and mortality in severe pancreatitis, compared with parenteral nutrition.
 The detection of infection of pancreatic necrosis is important for clinical decision making. Fine-needle aspiration may be
 used to confirm suspected ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277385</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:21 +0100</pubDate>
            <guid isPermaLink="false">2277385</guid>        </item>
        <item>
            <title>The changing character of acute pancreatitis: Epidemiology, etiology, and prognosis</title>
            <link>http://www.medworm.com/index.php?rid=2277387&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq705624180q76350%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Acute pancreatitis continues to be a diagnostic and therapeutic challenge for physicians and surgeons. It ranks third in the
 list of hospital discharges for gastro intestinal diseases. In most patients the cause is either gallstones or alcoholism.
 The overall mortality is less than 5%, but severe acute pancreatitis leads to prolonged hospitalization and much higher mortality.
 There are important differences in disease susceptibility and case fatality rates: the incidence is higher in blacks than
 in whites, and mortality is higher in older patients than in younger patients. Reports from various countries reveal that
 the frequency of acute pancreatitis is increasing, perhaps in relation to rising obesity rates, which would increase the likelihood
 of gallstone pancre...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277387</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:20 +0100</pubDate>
            <guid isPermaLink="false">2277387</guid>        </item>
        <item>
            <title>Endoscopic therapy for chronic pancreatitis: Technical success, clinical outcomes, and complications</title>
            <link>http://www.medworm.com/index.php?rid=2277386&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9212v8x43252037r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chronic pancreatitis (CP) can cause failure of both the exocrine and endocrine portions of the gland. Pain is the most recalcitrant
 clinical complaint in CP. Generally, conservative measures are first attempted to manage pain. These include cessation of
 alcohol use and smoking, enzyme replacement therapy, and finally, opioid analgesia. Endoscopy can be employed to treat the
 pain and complications due to CP. The results of the only two prospective randomized controlled trials suggest that surgery
 has a more durable effect than endoscopic therapy in controlling pain. Both trials suffer from severe limitations, however,
 and endoscopy remains the preferred approach for many patients because of its minimally invasive nature. Endoscopic ultrasound
 celiac plexus block ha...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277386</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:20 +0100</pubDate>
            <guid isPermaLink="false">2277386</guid>        </item>
        <item>
            <title>Antioxidants for chronic pancreatitis</title>
            <link>http://www.medworm.com/index.php?rid=2277389&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp8073267x5140347%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0014-6Authors
		Christopher E. Forsmark, University of Florida Division of Gastroenterology, Hepatology, and Nutrition Florida USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 2 / April, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277389</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:19 +0100</pubDate>
            <guid isPermaLink="false">2277389</guid>        </item>
        <item>
            <title>Spare the steroids, miss the diagnosis?</title>
            <link>http://www.medworm.com/index.php?rid=2277388&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgl71n100l8630311%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0015-5Authors
		John Baillie, Wake Forest University Health Sciences Section on Gastroenterology Winston-Salem USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 2 / April, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277388</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:19 +0100</pubDate>
            <guid isPermaLink="false">2277388</guid>        </item>
        <item>
            <title>Minimizing complications in pancreaticobiliary endoscopy</title>
            <link>http://www.medworm.com/index.php?rid=2277391&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7040vl85736h4w86%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound are invaluable tools in the diagnostic and
 therapeutic evaluation and management of a variety of pancreatobiliary disorders. Along with a significant refinement in the
 equipment and techniques used has come a recent trend toward aggressive therapeutic interventions. Because of the technical
 nature of these procedures and the characteristics of the patients, postprocedural complications may occur, ranging from minor
 (requiring brief hospitalization) to severe (causing permanent disability or death). This review summarizes these complications
 and outlines strategies to minimize them.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0021-7Authors
		Olga BarkayMouen KhashabMohammad Al-...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277391</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:18 +0100</pubDate>
            <guid isPermaLink="false">2277391</guid>        </item>
        <item>
            <title>The investigation of unexplained biliary dilatation</title>
            <link>http://www.medworm.com/index.php?rid=2277390&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff048363377k47165%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The investigation of biliary dilatation forms a routine part of gastroenterology practice. In developed countries, biliary
 dilatation is usually the result of obstruction of bile flow by either stones or mitotic lesions of the pancreas or biliary
 tree, and standard radiologic and endoscopic techniques are used to identify and relieve the obstruction. In the absence of
 an obvious cause, however, the investigation and management of biliary dilatation can prove challenging, particularly while
 trying to minimize invasive studies. This review examines factors thought to influence bile duct size in the absence of obvious
 obstructing pathology and looks at some causes of biliary dilatation that are unusual and potentially difficult to diagnose.
 
	Content Type Journal Art...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277390</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:18 +0100</pubDate>
            <guid isPermaLink="false">2277390</guid>        </item>
        <item>
            <title>Preoperative biliary drainage in malignant obstruction: Indications, techniques, and the debate over risk</title>
            <link>http://www.medworm.com/index.php?rid=2277392&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn70l4437j6r50642%2F</link>
            <description>This article examines the arguments for and against preoperative biliary drainage, the conflicting
 data on the subject, and the techniques used.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0022-6Authors
		Alan Coss, University of British Columbia Division of Gastroenterology 5135-2775 Laurel Street Vancouver BC V5Z 1M9 CanadaMichael F. Byrne
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 2 / April, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277392</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:17 +0100</pubDate>
            <guid isPermaLink="false">2277392</guid>        </item>
        <item>
            <title>Endoscopic ultrasound in the evaluation of radiologic abnormalities of the liver and biliary tree</title>
            <link>http://www.medworm.com/index.php?rid=2277393&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd1716526r68573g1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastroenterologists increasingly find themselves in the unenviable position of having to choose the optimal radiographic test
 to visualize the biliary tree and the liver. This dilemma is compounded by the rapid evolution of the available technologies
 and their ever-increasing resolution capabilities. Endoscopic ultrasound (EUS) has shown itself to be equally capable of providing
 detailed imaging of the biliary tree and of surrounding structures; its potential for evaluating liver lesions is just now
 being realized. EUS-fine needle aspiration (FNA) may supplant some of the existing technologies as it offers a way to sample
 masses, strictures, lymph nodes, and now certain segments of the liver and periportal regions. This review takes an in-depth
 look at the role of...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277393</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:15 +0100</pubDate>
            <guid isPermaLink="false">2277393</guid>        </item>
        <item>
            <title>ERCP in the management of biliary complications after cholecystectomy</title>
            <link>http://www.medworm.com/index.php?rid=2277394&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F55w2017844052621%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Open cholecystectomy has been associated historically with 0.2% to 0.5% risk of postoperative biliary injury. Laparoscopic
 cholecystectomy, which has become the first-line surgical treatment of calculous gallbladder disease, has been associated
 with a 2.5-fold to fourfold increase in the incidence of postoperative bile duct injury. The biliary endoscopist can expect
 to see a varied spectrum of complications after cholecystectomy by either technique, including postoperative biliary strictures,
 bile leaks, and retained calculi in the biliary tree. Proper diagnosis and treatment are paramount in ensuring a satisfactory
 outcome after bile duct injury. Endoscopic retrograde cholangiopancreatography (ERCP) has become the primary modality for
 treatment and effectively ma...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277394</comments>
            <pubDate>Tue, 17 Mar 2009 07:03:14 +0100</pubDate>
            <guid isPermaLink="false">2277394</guid>        </item>
        <item>
            <title>Treatment of chronic hepatitis B: Are we ready for combination therapy?</title>
            <link>http://www.medworm.com/index.php?rid=2116175&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9j7r1v52712t2u4t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Treatment of chronic hepatitis B virus (HBV) infection currently involves the use of immunomodulators such as interferon and
 nucleoside or nucleotide analogues. Treatment aims to suppress levels of HBV DNA and induce clearance of the hepatitis B e
 antigen (HBeAg) or surface antigen (HBsAg) and seroconversion. At present, no single treatment has been shown to reliably
 suppress HBV DNA and induce durable HBsAg loss. Nucleoside or nucleotide analogues induce the production of HBV-resistant
 mutations that may lead to virologic and clinical breakthrough. Combination therapy, using either immunomodulators in combination
 or with nucleoside or nucleotide analogues, represents an emerging strategy for treating chronic HBV infection. The theoretical
 benefits of combining ag...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116175</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:13 +0100</pubDate>
            <guid isPermaLink="false">2116175</guid>        </item>
        <item>
            <title>Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C</title>
            <link>http://www.medworm.com/index.php?rid=2116176&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq2505731n46813k1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Advanced liver disease and interferon-based treatment are both associated with varying degrees of cytopenia in patients with
 chronic hepatitis C. Growth factors to increase hemoglobin and neutrophils are commonly used in clinical practice, despite
 the absence of data to indicate benefits in terms of sustained viral response. Thrombocytopenia is observed frequently, is
 multifactorial in etiology, and may result in significant limitations on interventional and therapeutic options. A small-molecule
 thrombopoietin mimetic, eltrombopag, has demonstrated a dose-response associated increase in platelet count in a phase 2 study,
 allowing initiation and completion of a 12-week course of peginterferon plus ribavirin in 36%, 53%, and 65% of patients receiving
 30 mg, 50 mg, o...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116176</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:12 +0100</pubDate>
            <guid isPermaLink="false">2116176</guid>        </item>
        <item>
            <title>The impact of MELD allocation on simultaneous liver-kidney transplantation</title>
            <link>http://www.medworm.com/index.php?rid=2116177&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg4738k220g6538m1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Model for End-Stage Liver Disease (MELD) allocation has improved the process for ranking patients on the liver transplant
 list. One unintended consequence has been an increase in the number of simultaneous liver-kidney (SLK) transplants. Some have
 argued that the system unfairly advantages patients with kidney disease and that some kidneys are being prematurely placed
 in SLK transplantation. This review summarizes the MELD score, assessment of kidney function in cirrhosis, the impact of kidney
 function in liver disease, and changes in kidney function status in liver transplant recipients in the MELD era. Finally,
 recommendations regarding who should receive SLK transplants are reviewed.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0012-8Authors
		Julie A. ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116177</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:11 +0100</pubDate>
            <guid isPermaLink="false">2116177</guid>        </item>
        <item>
            <title>Hepatic assist devices: Will they ever be successful?</title>
            <link>http://www.medworm.com/index.php?rid=2116178&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F051471645q34850w%2F</link>
            <description>This article proposes goals for making a clinically useful BAL, with attention to systems biology and
 potential sources of hepatocytes.
 
	Content Type Journal ArticleDOI 10.1007/s11894-009-0010-xAuthors
		Norman L. Sussman, University of Utah 30 North 1900 East, SOM 4R118 Salt Lake City UT 84132-2410 USABrendan M. McGuireJames H. Kelly
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 1 / February, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116178</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:10 +0100</pubDate>
            <guid isPermaLink="false">2116178</guid>        </item>
        <item>
            <title>Nonalcoholic fatty liver disease and cardiovascular risk</title>
            <link>http://www.medworm.com/index.php?rid=2116179&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F775574lt08251110%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Nonalcoholic fatty liver disease (NAFLD) is a very common cause of chronic liver disease in the United States. A large proportion
 of patients with NAFLD have coexisting metabolic syndrome, a major risk factor for cardiovascular disease. A strong association
 between NAFLD and cardiovascular disease has been long suspected, and recent studies have confirmed that cardiovascular disease
 is the single most important cause of mortality in this patient population. NAFLD may pose cardiovascular risk beyond the
 risk conferred by traditional factors such as dyslipidemia, diabetes, and smoking. Health care providers managing patients
 with NAFLD should recognize this increased cardiovascular risk and should undertake early, aggressive risk factor modification.
 
	Content Type ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116179</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:08 +0100</pubDate>
            <guid isPermaLink="false">2116179</guid>        </item>
        <item>
            <title>Role of combination therapy in chronic hepatitis B</title>
            <link>http://www.medworm.com/index.php?rid=2116183&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm6872w465028k60j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Combination therapy includes the use of two or more antivirals for the treatment of chronic hepatitis B. No study has shown
 that combination therapy is superior to monotherapy in naive patients for achieving treatment end points, but combination
 appears to result in a lower incidence of resistance. Moreover, the higher-potency compounds have not yet been studied. Consideration
 should be given to treating lamivudine-resistant patients with combination therapy, preferably with a nucleotide analogue
 in conjunction with a nucleoside analogue. Combination therapy should be considered in patients with decompensated cirrhosis
 who are unable to achieve an undetectable viral level on monotherapy and in naive patients who still have a detectable viral
 level 6 to 12 months a...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116183</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:07 +0100</pubDate>
            <guid isPermaLink="false">2116183</guid>        </item>
        <item>
            <title>Lack of efficacy of maintenance interferon: Results of the HALT-C trial</title>
            <link>http://www.medworm.com/index.php?rid=2116182&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw64805540750x356%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-009-0001-yAuthors
		Bruce R. Bacon
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 11
	
		Journal Issue Volume 11, Number 1 / February, 2009 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116182</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:07 +0100</pubDate>
            <guid isPermaLink="false">2116182</guid>        </item>
        <item>
            <title>Small-duct primary sclerosing cholangitis</title>
            <link>http://www.medworm.com/index.php?rid=2116181&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6194408117162270%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Patients with cholestatic liver tests and typical histologic features of primary sclerosing cholangitis (PSC) but a normal
 cholangiogram have been identified as having small-duct PSC. This subgroup of PSC has been less well characterized than the
 classic largeduct form. Some patients characterized as having small-duct PSC develop cholangiographic features of PSC during
 follow-up. Three papers published in 2002 on small-duct PSC patients suggested a better prognosis in patients with small-duct
 PSC than in those with large-duct PSC. However, these studies included a limited number of patients and had a short follow-up.
 A combined cohort of these patients with a prolonged follow-up recently confirmed these previous observations. However, some
 patients will suffer fro...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116181</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:07 +0100</pubDate>
            <guid isPermaLink="false">2116181</guid>        </item>
        <item>
            <title>Treatment of chronic hepatitis C: Anticipated impact of resistance in patients treated with protease inhibitors</title>
            <link>http://www.medworm.com/index.php?rid=2116180&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe665j00852110q19%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A main target of specifically targeted antiviral therapy for hepatitis C (STAT-C) is the NS3-protease, which has key functions
 in the hepatitis C virus (HCV) replication cycle. HCV/NS3-protease inhibitors have shown high antiviral activity in vitro
 and in patients with chronic hepatitis C. Protease-resistant HCV variants occurred rapidly in patients receiving protease-inhibitor
 monotherapy. The development of resistance can be best explained by selection of preexisting resistant variants, which grow
 out under selective pressure. Numerous mutations associated with resistance were identified. Clinical trials showed that protease-resistant
 strains are sensitive to interferon and that a triple combination of protease inhibitors, peginterferon, and ribavirin may
 improv...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116180</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:07 +0100</pubDate>
            <guid isPermaLink="false">2116180</guid>        </item>
        <item>
            <title>Portopulmonary hypertension</title>
            <link>http://www.medworm.com/index.php?rid=2116185&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flv614l7h73k70954%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;It has been widely accepted that development of porto pulmonary hypertension (POPH) is independent of the cause of portal
 hypertension. The degree of hepatic damage and liver function do not correlate with predisposition to POPH or its severity.
 However, portal hypertension has been confirmed as a prerequisite for developing pulmonary hypertension. Transthoracic echocardiography
 is the best screening test for the presence of POPH, but a diagnosis of POPH can be established only by right heart catheterization.
 Randomized controlled trials comparing the efficacy and safety of different pharmacologic strategies are lacking in patients
 with POPH. The general management includes diuretics and oxygen supplementation. Notably, moderate to severe POPH predisposes
 candidat...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116185</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:05 +0100</pubDate>
            <guid isPermaLink="false">2116185</guid>        </item>
        <item>
            <title>Granulomatous liver disease</title>
            <link>http://www.medworm.com/index.php?rid=2116184&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv1241q0p677ug111%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hepatic granulomas are often encountered on liver biopsy and may represent a primary hepatic process, a manifestation of a
 systemic illness, or an innocent finding of no clinical relevance. Hepatic granulomas are a unique inflammatory response that
 may be idiopathic or may be a response to a bacterial, fungal, viral, or parasitic infection; a manifestation of drug-induced
 liver injury; or a manifestation of underlying malignancy. When granulomas are found on liver biopsy, clinicians must correlate
 the histologic findings with historical and clinical data to help provide an accurate diagnosis and guide management. Therapy
 may be warranted, either directly for the granulomatous inflammation of the liver or for a systemic process. For some patients,
 observation may b...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116184</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:05 +0100</pubDate>
            <guid isPermaLink="false">2116184</guid>        </item>
        <item>
            <title>Treating hepatocellular carcinoma without liver transplantation</title>
            <link>http://www.medworm.com/index.php?rid=2116187&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk8q7258231222188%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hepatocellular carcinoma, a significant health problem throughout the world, generally occurs in the setting of cirrhosis.
 Choice of treatment depends on the size and location of the tumor and hepatic reserve. Liver transplantation provides the
 best chance for long-term survival and can be performed regardless of hepatic reserve, but it requires small tumor sizes and
 is available to only a few patients. All other treatments require adequate hepatic reserve. Surgical resection, percutaneous
 ethanol injection, and radiofrequency ablation are effective treatments for patients with good hepatic reserve and small tumors
 isolated to the liver. For larger and multinodular tumors, chemoembolization is the best choice. With metastasis, portal vein
 invasion, or large biloba...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116187</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:03 +0100</pubDate>
            <guid isPermaLink="false">2116187</guid>        </item>
        <item>
            <title>Caring for adults with pediatric liver disease</title>
            <link>http://www.medworm.com/index.php?rid=2116186&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu766575557p8g111%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The etiology of liver disease in childhood varies significantly from its etiology in the adult population. More children with
 complex diseases are surviving into adulthood, providing challenges to the primary care provider. Adults with pediatric liver
 disease differ in management, treatment, complications, and extrahepatic considerations. To provide these patients with an
 optimal transition into the adult health care system, the provider needs a comprehensive knowledge of the common causes of
 childhood liver disease and their implications and must understand the differences in caring for these patients. This review
 addresses some of the most common childhood liver diseases, their causes, presentation, evaluation, management, complications,
 and additional concerns....</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2116186</comments>
            <pubDate>Sat, 17 Jan 2009 08:48:03 +0100</pubDate>
            <guid isPermaLink="false">2116186</guid>        </item>
        <item>
            <title>Hormonal regulation of gastric acid secretion</title>
            <link>http://www.medworm.com/index.php?rid=1991596&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F675k35398q26w787%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Although gastric acid is not essential for life, it facilitates the digestion of protein and the absorption of iron, calcium,
 vitamin B12, and thyroxin. It also prevents bacterial overgrowth and enteric infection. Gastric acid secretion must be precisely regulated,
 as too much acid may overwhelm mucosal defense mechanisms and lead to ulceration and maldigestion. The pathways regulating
 gastric acid secretion may be categorized as neural, paracrine, and hormonal; the hormonal pathways are the focus of this
 review. During meal ingestion, the main hormone responsible for stimulating acid secretion is gastrin, which acts primarily
 by releasing histamine from enterochromaffin-like cells. Ghrelin and orexin may also function as stimulatory hormones. Nutrients
 within the...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991596</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:24 +0100</pubDate>
            <guid isPermaLink="false">1991596</guid>        </item>
        <item>
            <title>From bugs to drugs—Mining the gut microbiota</title>
            <link>http://www.medworm.com/index.php?rid=1991595&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn117n11080828013%2F</link>
            <description>Content Type Journal ArticleCategory Invited CommentaryDOI 10.1007/s11894-008-0094-8Authors
		Fergus Shanahan, University College Cork, National University of Ireland Department of Medicine and Alimentary Pharmabiotic Centre College Road Cork Ireland
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991595</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:24 +0100</pubDate>
            <guid isPermaLink="false">1991595</guid>        </item>
        <item>
            <title>Is surveillance upper endoscopy indicated for gastric ulcers?</title>
            <link>http://www.medworm.com/index.php?rid=1991594&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ffp38684036lpm25n%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-008-0096-6Authors
		Joseph R. Pisegna
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991594</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:24 +0100</pubDate>
            <guid isPermaLink="false">1991594</guid>        </item>
        <item>
            <title>Web alert</title>
            <link>http://www.medworm.com/index.php?rid=1991593&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff11773t957272q7h%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11894-008-0095-7

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991593</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:24 +0100</pubDate>
            <guid isPermaLink="false">1991593</guid>        </item>
        <item>
            <title>Management of upper gastrointestinal bleeding</title>
            <link>http://www.medworm.com/index.php?rid=1991601&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk5755632624h835q%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Upper gastrointestinal bleeding secondary to ulcer disease is common and results in substantial patient morbidity and medical
 expense. After initial resuscitation to stabilize the patient, carefully performed endoscopy provides an accurate diagnosis
 and identifies high-risk ulcer patients who are likely to rebleed with medical therapy alone and will benefit most from endoscopic
 hemostasis. For patients with major stigmata of ulcer hemorrhage—active arterial bleeding, nonbleeding visible vessel, and
 adherent clot—combination therapy with epinephrine injection and either thermal coagulation (multipolar or heater probe) or
 endoclips is recommended. High-dose intravenous proton pump inhibitors are recommended as concomitant therapy after successful
 endoscopic hemo...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991601</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:23 +0100</pubDate>
            <guid isPermaLink="false">1991601</guid>        </item>
        <item>
            <title>Long-term proton pump inhibitor use and gastrointestinal cancer</title>
            <link>http://www.medworm.com/index.php?rid=1991600&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F442l114018206111%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Proton pump inhibitors profoundly affect the stomach and have been associated with carcinoid tumors in female rats. There
 is now sufficient experience with this class of drugs to allow reasonable estimation of their safety in terms of cancer development
 in humans. Long-term use of proton pump inhibitors is associated with an increase in gastric inflammation and development
 of atrophy among those with active Helicobacter pylori infections. The actual risk is unknown but is clearly low. However, it can be markedly reduced or eliminated by H. pylori eradication. It is thus recommended that patients being considered for long-term proton pump inhibitor therapy should be
 tested for H. pylori infection and, if present, this pathogen should be eradicated. Oxyntic cell hyper...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991600</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:23 +0100</pubDate>
            <guid isPermaLink="false">1991600</guid>        </item>
        <item>
            <title>Recent advances in IBD pathogenesis: Genetics and immunobiology</title>
            <link>http://www.medworm.com/index.php?rid=1991599&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fvr56141426036g44%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The inflammatory bowel diseases (IBDs), Crohn’s disease and ulcerative colitis, are chronic inflammatory disorders caused
 by dysregulated immune responses in genetically predisposed individuals. Although the precise etiology of IBD remains unclear,
 accumulating data, including genome-wide association studies, have advanced our understanding of its immunopathogenesis. This
 review highlights the role in gut homeostasis and IBD pathogenesis of autophagy, the interleukin (IL)-23/IL-17 axis, and a
 novel member of the tumor necrosis factor family, TL1A. It focuses on advances in our understanding of IBD from the past year,
 including advances in genetics and immunobiology.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0104-xAuthors
		David Q. Shih, Cedars-Sinai ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991599</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:23 +0100</pubDate>
            <guid isPermaLink="false">1991599</guid>        </item>
        <item>
            <title>Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib</title>
            <link>http://www.medworm.com/index.php?rid=1991598&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv3l02x6h12243wp2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastrointestinal stromal tumors (GIST) are rare tumors of mesenchymal origin that may arise anywhere along the gastrointestinal
 tract or in the peritoneum. In most cases, GIST harbor mutations of KIT or PDGFRA. Imatinib mesylate (IM), a small-molecule tyrosine kinase inhibitor developed for the treatment of chronic myeloid leukemia,
 has been shown to be active against these mutations and has significant activity in patients with metastatic GIST. However,
 resistance to IM emerges after a median of 24 months of treatment. Sunitinib malate (SU) has been approved for the treatment
 of patients with IM-resistant advanced GIST, but the median progression-free survival in this setting is only 6 months. This
 article reviews the current knowledge regarding IM and SU resistan...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991598</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:23 +0100</pubDate>
            <guid isPermaLink="false">1991598</guid>        </item>
        <item>
            <title>Optimizing conventional therapy for inflammatory bowel disease</title>
            <link>http://www.medworm.com/index.php?rid=1991597&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm11422x121u11t72%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recently, conventional therapies for inflammatory bowel disease (IBD) have not received the same amount of attention as biologic
 therapies, yet they remain the backbone of therapy for IBD because of their efficacy, safety, and relatively low cost. Advances
 in efficacy and safety continue because of modifications in drug dosing and monitoring. Higher doses of mesalamine per pill,
 together with once-daily dosing, may help to optimize drug delivery and patient compliance. Budesonide, an effective agent
 for both induction and short-term remission maintenance in Crohn’s disease, is devoid of many of the toxicities common to
 corticosteroids. Assessments of thiopurine methyltransferase and metabolite levels are helping to fine-tune dose optimization
 for the thiopurines...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991597</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:23 +0100</pubDate>
            <guid isPermaLink="false">1991597</guid>        </item>
        <item>
            <title>Biologic therapy for inflammatory bowel disease comes of age</title>
            <link>http://www.medworm.com/index.php?rid=1991604&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2001372724160t8w%2F</link>
            <description>Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11894-008-0103-yAuthors
		Stephen B. Hanauer
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991604</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:22 +0100</pubDate>
            <guid isPermaLink="false">1991604</guid>        </item>
        <item>
            <title>Gastroduodenal mucosal defense</title>
            <link>http://www.medworm.com/index.php?rid=1991603&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj32190707348385r%2F</link>
            <description>This article also summarizes
 some new findings on the genetics of ulcer formation and the effects of age and gender on mucosal defense and touches on current
 developments in drugs, including considerations for future therapeutic agents.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0101-0Authors
		Amy ZhuJonathan Kaunitz, West Los Angeles VA Medical Center Building 114, Suite 217 11301 Wilshire Boulevard Los Angeles CA 90073 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 6 / December, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991603</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:22 +0100</pubDate>
            <guid isPermaLink="false">1991603</guid>        </item>
        <item>
            <title>Pharmacology of proton pump inhibitors</title>
            <link>http://www.medworm.com/index.php?rid=1991602&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft16008551823r09t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The gastric H,K-ATPase is the primary target for the treatment of acid-related diseases. Proton pump inhibitors (PPIs) are
 weak bases composed of two moieties, a substituted pyridine with a primary pKa of about 4.0, which allows selective accumulation in the secretory canaliculus of the parietal cell, and a benzimidazole
 with a second pKa of about 1.0. PPIs are acid-activated prodrugs that convert to sulfenic acids or sulfenamides that react covalently with
 one or more cysteines accessible from the luminal surface of the ATPase. Because of covalent binding, their inhibitory effects
 last much longer than their plasma half-life. However, the short half-life of the drug in the blood and the requirement for
 acid activation impair their efficacy in acid suppression, par...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991602</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:22 +0100</pubDate>
            <guid isPermaLink="false">1991602</guid>        </item>
        <item>
            <title>Managing medical complications and recurrence after surgery for Crohn’s disease</title>
            <link>http://www.medworm.com/index.php?rid=1991608&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0n72u3784076m343%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Each of the medical and surgical therapies for Crohn’s disease has inherent advantages and disadvantages that must be balanced
 for patients with moderate to severe disease. Most patients with Crohn’s disease require surgery at some point during the
 lifelong illness, but surgical therapy is not curative for most patients, as postoperative recurrence of Crohn’s disease is
 common and can pose diagnostic and therapeutic challenges. Disease monitoring and appropriate prophylaxis are necessary in
 patients at high risk.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0109-5Authors
		Bo Shen, Cleveland Clinic Digestive Disease Institute 9500 Euclid Avenue Cleveland OH 44195 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991608</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:21 +0100</pubDate>
            <guid isPermaLink="false">1991608</guid>        </item>
        <item>
            <title>Extraintestinal manifestations of inflammatory bowel disease</title>
            <link>http://www.medworm.com/index.php?rid=1991607&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg2x3518332701801%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The idiopathic inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis, may be complicated by extraintestinal
 manifestations (EIMs) in up to 40% of patients. Reports suggest that almost every organ system may be affected. The EIMs are
 a significant cause of morbidity and may be particularly distressing for the patient. Recent attempts have been made to define
 the phenotype of IBD in patients of different ethnicities. These studies have highlighted potential racial variations in the
 prevalence of specific EIMs, findings that are perhaps not surprising given the influence of genetic factors in their pathogenesis.
 Certain EIMs are related to the activity of the bowel disease, and their management often involves careful monitoring while
 the IBD is ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991607</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:21 +0100</pubDate>
            <guid isPermaLink="false">1991607</guid>        </item>
        <item>
            <title>Optimizing treatment of inflammatory bowel diseases with biologic agents</title>
            <link>http://www.medworm.com/index.php?rid=1991606&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F157622233w29255x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Despite more than a decade of clinical experience in the treatment of inflammatory bowel disease with biologic agents, particularly
 anti-tumor necrosis factor (TNF) antibodies, optimal treatment strategies are still debated. Secondary loss of response due
 to immuno genicity is intrinsic to the use of therapeutic antibodies and has important implications. With the chimeric anti-TNF
 antibody, infliximab, scheduled maintenance therapy minimizes the risk of loss of response, and there is no clear evidence
 that concomitant immunosuppressives have added value in this setting. More humanized anti-TNF antibodies have entered clinical
 practice, opening new perspectives to patients with inflammatory bowel disease, but interventions in the dosing regimen remain
 necessary for...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991606</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:21 +0100</pubDate>
            <guid isPermaLink="false">1991606</guid>        </item>
        <item>
            <title>Advances in epidemiology and diagnosis of inflammatory bowel diseases</title>
            <link>http://www.medworm.com/index.php?rid=1991605&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh7qh5t8212062113%2F</link>
            <description>This article reviews recent advances in epidemiology and diagnostics. The importance of Clostridium difficile is highlighted. State-of-the-art IBD diagnostic modalities include serology, fecal markers, and advanced radiologic or endoscopic
 techniques. These include wireless capsule endoscopy, balloon enteroscopy, chromoendoscopy, high-magnification endoscopy,
 and MRI. The increasing number of available modalities requires appreciation of their indications, strengths, and limitations.
 This article discusses these issues relevant to the clinician.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0105-9Authors
		Sobia AliCyrus P. Tamboli, University of Iowa Carver College of Medicine 4614 JCP, Department of Internal Medicine 200 Hawkins Drive Iowa City IA 52242 USA
	

	
		Journal Curr...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991605</comments>
            <pubDate>Tue, 25 Nov 2008 06:58:21 +0100</pubDate>
            <guid isPermaLink="false">1991605</guid>        </item>
        <item>
            <title>Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children</title>
            <link>http://www.medworm.com/index.php?rid=1901996&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa026l804v104l478%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The single biggest change in the approach to treating pediatric gastroesophageal reflux disease (GERD) in recent years has
 been the empiric use of proton pump inhibitors (PPIs) for symptoms suspected to be those of GERD. In other words, PPIs have
 been used increasingly as a first-line concurrent diagnostic test and treatment before any investigation. Although this approach
 is useful for some patients, there are a number of caveats about its application to children. In general, these caveats are
 related to age per se (eg, infancy) and to age-related symptoms and severity of GERD itself. The most important caveats relate
 to the prescription of empiric PPI therapy in infants—which generally is to be avoided—and to how PPIs are used in older children—specifically...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1901996</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:58 +0100</pubDate>
            <guid isPermaLink="false">1901996</guid>        </item>
        <item>
            <title>Acute mesenteric ischemia</title>
            <link>http://www.medworm.com/index.php?rid=1901995&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft87j208v41610005%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Acute mesenteric ischemia is caused by a critical reduction in intestinal blood flow that frequently results in bowel necrosis
 and is associated with a high mortality. Clinicians must maintain a high index of suspicion because a prompt diagnosis and
 early aggressive treatment before the onset of bowel infarction results in reduced mortality. Medical management includes
 aggressive rehydration and the use of antibiotics, anticoagulation, vasodilators, and inhibitors of reperfusion injury. If
 acute mesenteric ischemia is suspected, early angiography is imperative, as it permits accurate diagnosis and possible therapeutic
 intervention. Therapeutic options during angiography depend on the cause of ischemia and include administering intra-arterial
 vasodilators and/or th...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1901995</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:58 +0100</pubDate>
            <guid isPermaLink="false">1901995</guid>        </item>
        <item>
            <title>Biliary dyskinesia in the pediatric patient</title>
            <link>http://www.medworm.com/index.php?rid=1901994&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft4ml405942336747%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The term biliary dyskinesia commonly describes a motility disorder of the biliary tract that is divided into two main categories: gallbladder dyskinesia
 (GBD) and sphincter of Oddi dysfunction (SOD). SOD is further subdivided into biliary SOD and pancreatic SOD. GBD causes typical
 biliary colic without gallstones, whereas SOD typically presents with recurrent pancreatitis or chronic abdominal pain, usually
 after cholecystectomy. GBD and SOD are uncommon in children. Based on adult experience, this review discusses the diagnosis
 and treatment of GBD and SOD in the pediatric population.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0064-1Authors
		Michael S. Halata, Maria Fareri Children’s Hospital, New York Medical College Department of Pediatric Gastroente...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1901994</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:58 +0100</pubDate>
            <guid isPermaLink="false">1901994</guid>        </item>
        <item>
            <title>Clinical trials report</title>
            <link>http://www.medworm.com/index.php?rid=1902001&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy20587j525g27352%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11894-008-0058-zAuthors
		Susan R. Orenstein
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 3 / June, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902001</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:57 +0100</pubDate>
            <guid isPermaLink="false">1902001</guid>        </item>
        <item>
            <title>Factors influencing functional abdominal pain in children</title>
            <link>http://www.medworm.com/index.php?rid=1902000&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F83666456m224h312%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Functional gastrointestinal disorders (FGIDs) commonly affect children and are associated with short-and long-term morbidity.
 Although the pathogenesis of pain-related FGIDs remains incompletely understood, most investigators agree on a multifactorial
 etiology and the presence of an altered brain-gut interaction. A continuous interplay of genetic and environmental factors
 appears to shape the development of the central and enteric nervous systems. The biopsychosocial model is the current operational
 framework for children with FGIDs, as it recognizes the interaction between social and environmental influences and psychological
 and physiologic processes. The biopsychosocial model proposes that specific permutations of genetic susceptibility, early
 life experiences,...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902000</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:57 +0100</pubDate>
            <guid isPermaLink="false">1902000</guid>        </item>
        <item>
            <title>Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease</title>
            <link>http://www.medworm.com/index.php?rid=1901999&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F866512301385574q%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Infliximab is approved for the induction and 1-year maintenance of remission in pediatric Crohn’s disease unresponsive to
 conventional therapy. Despite significant experience with the use of this agent in children and adolescents who have inflammatory
 bowel disease, many questions about its optimal use remain. Recent safety concerns raised debate over the common practice
 of using infliximab in combination with conventional immunomodulatory agents. Additionally, although regularly scheduled administration
 maintains remission more effectively than episodic therapy, it is not known whether all patients who start infliximab must
 continue it for maintenance. Some patients may be able to use infliximab for induction and another agent for maintenance.
 Finally, the opti...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1901999</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:57 +0100</pubDate>
            <guid isPermaLink="false">1901999</guid>        </item>
        <item>
            <title>Nutrition and nonalcoholic fatty liver disease in children</title>
            <link>http://www.medworm.com/index.php?rid=1901998&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1365564266338245%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Nonalcoholic fatty liver disease (NAFLD) is an obesity-associated liver disease found in 3% to 9% of children in the United
 States. NAFLD represents a spectrum of liver disease and is frequently associated with features of the metabolic syndrome.
 Nutrition’s role in NAFLD is complex. It does not appear that overweight children with NAFLD have an unusual diet compared
 with their overweight counterparts without NAFLD. It is more likely that they have increased genetic susceptibility to the
 general poor diet and state of positive calorie balance currently found in many children. The available treatment studies
 using nutrition counseling and increased physical activity are promising. We recommend initiating sustainable family-oriented
 lifestyle changes in all childr...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1901998</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:57 +0100</pubDate>
            <guid isPermaLink="false">1901998</guid>        </item>
        <item>
            <title>Patterns of gastrointestinal disease associated with mutations of 
 CFTR</title>
            <link>http://www.medworm.com/index.php?rid=1901997&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh7322p26xx334721%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This review focuses on the pathobiology of the gastrointestinal and hepatic manifestations of cystic fibrosis (CF) disease
 in relation to their genetic basis in mutations of the CF transmembrane conductance regulator (CFTR) gene. It reviews the nature of the CFTR protein, a categorization of the types of gene mutations underlying CF’s various
 manifestations, and the ways in which absent or reduced CFTR produces various functional abnormalities in the different organs
 affected by CF. Subsequently, the particular organ-related clinical manifestations of CF directly associated with loss of
 CFTR function are addressed. Thereafter, the review discusses some of the complexities of the genotype-phenotype relationships
 related to milder mutations or complex genetic disor...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1901997</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:57 +0100</pubDate>
            <guid isPermaLink="false">1901997</guid>        </item>
        <item>
            <title>Analysis of 24-hour esophageal pH monitoring: The effect of state of consciousness</title>
            <link>http://www.medworm.com/index.php?rid=1902006&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F59t1662377221v11%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This review addresses current advances in the diagnosis of sleep-related gastroesophageal reflux using ambulatory esophageal
 pH monitoring and laboratory monitoring, which includes polygraphic assessment of the state of consciousness. This 24-hour
 pH monitoring uses a new strategy of interpretation that characterizes acidic reflux events and specifically assesses the
 patient’s position and state of consciousness. Thus, the recognition of reflux events during waking and sleep will add to
 the overall assessment of gastroesophageal reflux and its severity and clinical relevance. The pH testing, together with overnight
 polysomnography, offers an opportunity to link nighttime reflux with disease severity. The application of multichannel impedance
 with pH monitoring a...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902006</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:56 +0100</pubDate>
            <guid isPermaLink="false">1902006</guid>        </item>
        <item>
            <title>Reflux monitoring: Current status</title>
            <link>http://www.medworm.com/index.php?rid=1902005&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw82k377737u13045%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastroesophageal reflux monitoring is a key investigation in managing gastroesophageal reflux disease. Esophageal pH monitoring
 is used to quantify esophageal acid exposure and the association of symptoms with acidic reflux episodes. Recently available
 wireless pH monitoring systems allow reflux monitoring over prolonged periods and increase patient comfort during the procedure.
 Combined impedance-pH monitoring offers the ability to identify reflux episodes independently of their acid content, an important
 advantage when evaluating patients with symptoms persisting during acid-suppressive therapy.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0054-3Authors
		Radu Tutuian, University Hospital Zurich Division of Gastroenterology and Hepatology Ramistrasse 100 ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902005</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:56 +0100</pubDate>
            <guid isPermaLink="false">1902005</guid>        </item>
        <item>
            <title>Laryngeal manifestations of gastroesophageal reflux disease</title>
            <link>http://www.medworm.com/index.php?rid=1902004&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe81w6785485878m7%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Chronic laryngeal signs and symptoms associated with gastroesophageal reflux disease (GERD) are often referred to as reflux laryngitis or laryngopharyngeal reflux (LPR). It is estimated that up to 15% of all visits to otolaryngology offices are because of manifestations of LPR. Damage
 to laryngeal mucosa may be the result of reflux of gastroduodenal contents, whether chronic or a single incident. The most
 common presenting symptoms of LPR include hoarseness, sore throat, throat clearing, and chronic cough. The diagnosis of LPR
 is usually made on the basis of presenting symptoms and associated laryngeal signs, including laryngeal edema and erythema.
 The current recommendation for managing these patients is empiric therapy with twice-daily proton pump inhibitors for 1...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902004</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:56 +0100</pubDate>
            <guid isPermaLink="false">1902004</guid>        </item>
        <item>
            <title>Laryngopharyngeal reflux: The value of otolaryngology examination</title>
            <link>http://www.medworm.com/index.php?rid=1902003&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn745j35577776303%2F</link>
            <description>This article discusses the current understanding of LPR pathophysiology, taking into account pepsin stability and
 reactivation.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0056-1Authors
		Peter C. Belafsky, University of California, Davis School of Medicine Center for Voice and Swallowing, Department of Otolaryngology Head and Neck Surgery 2521 Stockton Boulevard, Suite 7200 Sacramento CA 95817 USACatherine J. Rees
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 3 / June, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902003</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:56 +0100</pubDate>
            <guid isPermaLink="false">1902003</guid>        </item>
        <item>
            <title>Diagnostic options for patients with refractory GERD</title>
            <link>http://www.medworm.com/index.php?rid=1902002&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7742w0l7h6j36105%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Patients with refractory gastroesophageal reflux disease (GERD) are those who have persistent symptoms while being treated
 with proton pump inhibitors (PPIs). One third of GERD patients requiring a daily PPI are estimated to eventually experience
 treatment failure. These patients are usually referred for further investigation to confirm the presence of GERD or to identify
 other entities as the cause of symptoms. Tools that can be used in this diagnostic process include upper gastrointestinal
 endoscopy with analysis of esophageal biopsies, esophageal pH monitoring, impedance-pH monitoring, and esophageal bilirubin
 monitoring. The conventional diagnostic approach includes upper gastrointestinal endoscopy and ambulatory pH monitoring while
 receiving PPI therapy. New ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902002</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:56 +0100</pubDate>
            <guid isPermaLink="false">1902002</guid>        </item>
        <item>
            <title>The value of esophageal histology in the diagnosis of gastroesophageal reflux disease in patients with heartburn and normal endoscopy</title>
            <link>http://www.medworm.com/index.php?rid=1902011&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj0r44jp6405t8253%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Histologic markers of reflux-induced mucosal injury are demonstrable in patients with nonerosive gastroesophageal reflux disease
 (neGERD). They include papillary elongation, basal cell hyperplasia, and dilation of intercellular spaces, especially of the
 prickle layer. These abnormalities are responsive to acid-suppressive therapy. Unfortunately, the longitudinal and circumferential
 distributions of these anomalies are nonuniform. They are presumably focalized on top of the esophageal folds, where the brunt
 of acid exposure and injury occurs. Therefore, based on current evidence, routine, random, nontargeted biopsies of the distal
 esophagus cannot be recommended in patients with neGERD. This may change if future studies reveal a high sensitivity and specificity
 of ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902011</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:55 +0100</pubDate>
            <guid isPermaLink="false">1902011</guid>        </item>
        <item>
            <title>Reflux cough</title>
            <link>http://www.medworm.com/index.php?rid=1902010&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F36111473k52q538r%2F</link>
            <description>This article summarizes recent progress
 in our understanding of the pathophysiology, diagnosis, and treatment of the reflux cough syndrome. Recent studies have provided
 further evidence for a role of weakly acidic gastroesophageal reflux in inducing cough. It has also been established that
 although reflux may induce cough, cough may also trigger reflux in some patients, and distinguishing between the two requires
 objective detection of cough burst (ie, by esophageal manometry). Treatment of the reflux cough syndrome is an issue of ongoing
 controversy and further studies.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0049-0Authors
		Kathleen BlondeauDaniel SifrimLieven DupontJan Tack, University of Leuven Department of Pathophysiology, Division of Gastroenterology Herestraat 49...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902010</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:55 +0100</pubDate>
            <guid isPermaLink="false">1902010</guid>        </item>
        <item>
            <title>Management of high-grade dysplasia</title>
            <link>http://www.medworm.com/index.php?rid=1902009&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu5450461887g261r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;High-grade dysplasia is the last stage before the development of adenocarcinoma. Despite the fact that the lesion is not yet
 invasive, it has tremendous potential to become malignant. The approach to the disease has clinicians divided between immediate
 intervention with surgical resection or continued endoscopic surveillance proof of the unclear natural history. Much knowledge
 has been acquired recently regarding application of surveillance and outcomes of esophageal resection. Also, many endoscopic
 techniques for treating high-grade dysplasia have been studied in depth. Results on their safety, efficacy, and complication
 rates have recently become available. This review analyzes the progress in the understanding and treatment of high-grade dysplasia
 during the pa...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902009</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:55 +0100</pubDate>
            <guid isPermaLink="false">1902009</guid>        </item>
        <item>
            <title>Biomechanics of the esophagogastric junction in gastroesophageal reflux disease</title>
            <link>http://www.medworm.com/index.php?rid=1902008&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fur003010g7g62248%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastroesophageal reflux is inherently mechanical in nature, driven by the pressure difference between the stomach and the
 esophagus in the setting of a relaxed or hypotensive sphincter. Recent advances in our understanding of esophagogastric junction
 (EGJ) biomechanics in the etiology of gastroesophageal reflux disease are highlighted here. We focus this review on three
 critical areas: the anatomy and physiology of the EGJ that predispose the junction to reflux, the mechanical compliance of
 the EGJ musculature that has significant pathophysiologic underpinnings, and the trans-sphincteric pressure gradients during
 gastro-esophageal reflux. We also examine the mechanistic basis of a higher incidence of reflux in obese patients and conclude
 with some observations on ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902008</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:55 +0100</pubDate>
            <guid isPermaLink="false">1902008</guid>        </item>
        <item>
            <title>Refractory GERD: What is it?</title>
            <link>http://www.medworm.com/index.php?rid=1902007&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flm15v813n0tnr053%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Refractory gastroesophageal reflux disease (GERD) is very common and may affect up to 40% of patients who use a proton pump
 inhibitor (PPI) once daily. Refractory GERD can present as incomplete or lack of response to PPI therapy. The disorder is
 clearly driven by patients, who present with a wide range of symptom severity and frequency while on PPI treatment. Poor compliance
 and improper timing of PPI consumption should always be excluded before further evaluation of this patient population. The
 putative mechanisms for refractory GERD include weakly acidic reflux, duodenogastroesophageal/bile reflux, visceral hypersensitivity,
 delayed gastric emptying, psychological comorbidity, and concomitant functional bowel disorders. Reduced PPI bioavailability,
 rapid PPI met...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902007</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:55 +0100</pubDate>
            <guid isPermaLink="false">1902007</guid>        </item>
        <item>
            <title>Potential adverse effects of proton pump inhibitors</title>
            <link>http://www.medworm.com/index.php?rid=1902013&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F91608505g586h1x1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Proton pump inhibitors (PPIs) have revolutionized the management of gastroesophageal reflux disease and peptic ulcer disease
 over the past two decades. Among the most commonly prescribed agents worldwide, PPIs’ overall safety profile is unquestionable.
 However, emerging evidence indicates that PPI therapy, particularly with long-term and/or high-dose administration, is associated
 with several potential adverse effects, including enteric infections (eg, Clostridium difficile), community-acquired pneumonia, and hip fracture, all of which have received much attention recently. We review the current
 data on these and other potential consequences of PPI therapy. More judicious use of PPIs (eg, administering them in no more
 than the minimum effective dose to older adul...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902013</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:54 +0100</pubDate>
            <guid isPermaLink="false">1902013</guid>        </item>
        <item>
            <title>New esophageal function testing (impedance, Bravo pH monitoring, and high-resolution manometry): Clinical relevance</title>
            <link>http://www.medworm.com/index.php?rid=1902012&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2k08320x7r2757g9%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Esophageal testing aims to quantify gastroesophageal reflux or characterize esophageal motility. Reflux monitoring traditionally
 has been based on the detection of acidic reflux by a transnasal catheter that measures esophageal pH. Recently there have
 been two major developments in this field: the wireless Bravo pH capsule (Medtronic, Inc., Minneapolis, MN), which allows
 catheter-free monitoring, and impedance-pH measurement, a catheter-based technique that enables detection of acidic and nonacidic
 reflux. The assessment of esophageal motility has relied on conventional manometry for many years. Two new proedures also
 recently became available to assess esophageal motility: high-resolution manometry, which uses many closely spaced pressure
 sensors and provides spa...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1902012</comments>
            <pubDate>Tue, 21 Oct 2008 14:41:54 +0100</pubDate>
            <guid isPermaLink="false">1902012</guid>        </item>
        <item>
            <title>Web alert</title>
            <link>http://www.medworm.com/index.php?rid=1886713&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk510536m7134h113%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11894-008-0067-y

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886713</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:33 +0100</pubDate>
            <guid isPermaLink="false">1886713</guid>        </item>
        <item>
            <title>Clinical trials report</title>
            <link>http://www.medworm.com/index.php?rid=1886712&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc1159h3773516316%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11894-008-0068-xAuthors
		Amy E. Foxx-Orenstein
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886712</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:33 +0100</pubDate>
            <guid isPermaLink="false">1886712</guid>        </item>
        <item>
            <title>Salmonellosis and the gastrointestinal tract: More than just peanut butter</title>
            <link>http://www.medworm.com/index.php?rid=1886718&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1014567131617203%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Nontyphoidal salmonellosis is the leading cause of foodborne illness in the United States, causing about 1.4 million infections
 annually. Most cases of salmonellosis are due to ingestion of contaminated food items such as eggs, dairy products, and meats,
 but almost any foodstuff can be implicated, including peanut butter, as seen during a recent outbreak of more than 600 Salmonella infections. Although outbreaks often gain national media attention, the majority of nontyphoidal Salmonella infections in the United States occur sporadically. Risk factors for salmonellosis include gastric hypoacidity, recent use
 of antibiotics, extremes of age, and immunosuppressive conditions. Clinical manifestations of the infection most commonly
 involve self-limited gastroenteritis, ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886718</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:32 +0100</pubDate>
            <guid isPermaLink="false">1886718</guid>        </item>
        <item>
            <title>Genes and irritable bowel syndrome: Is there a link?</title>
            <link>http://www.medworm.com/index.php?rid=1886717&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr82546178ml7804l%2F</link>
            <description>This article summarizes the evidence for and against a link between genes and IBS. In addition, a gene-environment paradigm
 is presented to combine the two opposing hypotheses, as IBS may represent a complex genetic disorder that results from the
 interaction of several genes and environmental risk factors.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0069-9Authors
		Yuri A. Saito, Mayo Clinic Miles and Shirley Fiterman Center for Digestive Disease 200 First Street SW Rochester MN 55905 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886717</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:32 +0100</pubDate>
            <guid isPermaLink="false">1886717</guid>        </item>
        <item>
            <title>Are there too many practice guidelines for acute pancreatitis?</title>
            <link>http://www.medworm.com/index.php?rid=1886716&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr1674k3471270u77%2F</link>
            <description>Content Type Journal ArticleCategory Invited CommentaryDOI 10.1007/s11894-008-0066-zAuthors
		Chris E. Forsmark, University of Florida Division of Gastroenterology, Hepatology, and Nutrition Box 100214 Gainesville FL 32610-0214 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886716</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:32 +0100</pubDate>
            <guid isPermaLink="false">1886716</guid>        </item>
        <item>
            <title>The role of serotonin in irritable bowel syndrome: Implications for management</title>
            <link>http://www.medworm.com/index.php?rid=1886715&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fjk0683n517910x98%2F</link>
            <description>This article reviews the evidence
 that serotonin, one of the better-understood neurotransmitters with respect to its role in human central and intestinal physiology,
 plays a role in IBS. Serotonin signaling is discussed, with a focus on receptor subtypes and the therapeutic agents that target
 these receptors. Evidence that IBS is associated with perturbations in serotonin metabolism at various steps in the signaling
 pathway is also addressed, along with the limitations on alteration in serotonin metabolism as the sole explanation for the
 constellation of symptoms observed in patients with IBS.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0070-3Authors
		Brian GarvinJohn W. Wiley, University of Michigan Health System Department of Internal Medicine A7007 UH, 1500 East Medical ...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886715</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:32 +0100</pubDate>
            <guid isPermaLink="false">1886715</guid>        </item>
        <item>
            <title>Novel techniques to study visceral hypersensitivity in irritable bowel syndrome</title>
            <link>http://www.medworm.com/index.php?rid=1886714&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F34q5850n65h1304h%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Visceral hypersensitivity has emerged as a key hypothesis in explaining the painful symptoms of irritable bowel syndrome (IBS),
 and it has been proposed as a “biologic marker” for the condition. Visceral hypersensitivity can be influenced by peripheral
 and central mechanisms affecting pain perception. The optimal method for its assessment in humans has not been determined.
 Current techniques include stimulation via the computerized barostat and electrical stimulation, response measures including
 the lower limb reflex, and brain imaging modalities such as functional MRI and positron emission tomography. It has been shown
 that IBS patients have decreased sensory thresholds to colonic and rectal balloon distention by barostat. Studies using electrical
 stimulation...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886714</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:32 +0100</pubDate>
            <guid isPermaLink="false">1886714</guid>        </item>
        <item>
            <title>The human gut microbiome: Implications for future health care</title>
            <link>http://www.medworm.com/index.php?rid=1886722&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7882k18k2085457l%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In their intestine, humans possess an “extended genome” of millions of microbial genes—the microbiome. Because this complex
 symbiosis influences host metabolism, physiology, and gene expression, it has been proposed that humans are complex biologic
 “superorganisms.” Advances in microbiologic analysis and systems biology are now beginning to implicate the gut microbiome
 in the etiology of localized intestinal diseases such as the irritable bowel syndrome, inflammatory bowel disease, and colon
 cancer. These approaches also suggest possible links between the gut and previously unassociated systemic conditions such
 as type 2 diabetes and obesity. The elucidation of the intestinal microbiome is therefore likely to underpin future disease
 prevention strategies...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886722</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:31 +0100</pubDate>
            <guid isPermaLink="false">1886722</guid>        </item>
        <item>
            <title>Gastrointestinal cytomegalovirus disease in the immunocompromised patient</title>
            <link>http://www.medworm.com/index.php?rid=1886721&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fywtn170681762138%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cytomegalovirus (CMV) has emerged as a significant opportunistic pathogen in the era of immunosuppression. CMV was a common
 cause of gastrointestinal disease in AIDS patients, but the introduction of highly active antiretroviral therapy has led to
 a dramatic decline in AIDS-related disease. Among patients with solid organ transplants, CMV has become an increasingly important
 cause of gastrointestinal disease as more routine use of early CMV prophylaxis has increased delayed-onset disease, which
 is often tissue invasive at presentation. The role of CMV in inflammatory bowel disease is controversial; treatment may be
 indicated in selected cases of steroid-refractory disease with evidence of CMV. Diagnosis of gastrointestinal CMV disease
 generally requires endoscopic...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886721</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:31 +0100</pubDate>
            <guid isPermaLink="false">1886721</guid>        </item>
        <item>
            <title>Clostridium difficile
 infection: Emerging concepts and treatments</title>
            <link>http://www.medworm.com/index.php?rid=1886720&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0506203132358021%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 Clostridium difficile infection has become one of the most common causes of diarrhea in patients frequenting hospitals, skilled nursing facilities,
 and physicians’ offices. Although the pathogenesis and clinical description were well elucidated three decades ago, cure during
 the initial episode now occurs in fewer than two thirds of patients exhibiting clinical illness. The past decade has brought
 a new strain with more toxin. Frequent relapses in elderly patients are now the norm rather than a rarity. This review is
 intended to update clinicians regarding diagnosis, infection control, and treatment, including treatment of the difficult-to-treat
 patient with multiple relapses of C. difficile infection.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0076-...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886720</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:31 +0100</pubDate>
            <guid isPermaLink="false">1886720</guid>        </item>
        <item>
            <title>Herpes simplex virus and the alimentary tract</title>
            <link>http://www.medworm.com/index.php?rid=1886719&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg7k7t530110w7574%2F</link>
            <description>This article reviews the manifestations of HSV infection within the luminal
 gastrointestinal tract and options for diagnosis and treatment.
 
	Content Type Journal ArticleDOI 10.1007/s11894-008-0078-8Authors
		Eric A. LaveryWalter J. Coyle, Division of Gastroenterology and Hepatology Scripps Clinic Torrey Pines 10666 North Torrey Pines Road, N203 La Jolla CA 92037 USA
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886719</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:31 +0100</pubDate>
            <guid isPermaLink="false">1886719</guid>        </item>
        <item>
            <title>The measurement and clinical significance of intestinal permeability</title>
            <link>http://www.medworm.com/index.php?rid=1886727&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl9712x4263113467%2F</link>
            <description>This article discusses the concept of intestinal permeability and the barrier function of the gut, elaborates on tight junction
 structure and the dynamic nature of its composition, outlines the methods for evaluating intestinal permeability, and explores
 abnormal intestinal permeability in clinical disease, emphasizing its possible role in the pathogenesis of autoimmune conditions.
 Evidence is provided from several representative diseases for a proposed model of abnormal intestinal permeability in autoimmune
 disease, including a description of a molecular pathway involving a signaling protein called zonulin, which appears to regulate
 intestinal permeability. Finally, we speculate on mechanisms that may be responsible for increasing intestinal permeability
 and consider clinical implic...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886727</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:30 +0100</pubDate>
            <guid isPermaLink="false">1886727</guid>        </item>
        <item>
            <title>A roadmap for understanding and preventing necrotizing enterocolitis</title>
            <link>http://www.medworm.com/index.php?rid=1886726&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F564n00898017887j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Necrotizing enterocolitis (NEC) is the most common severe gastrointestinal emergency that affects newborns. Its etiology is
 still undetermined. Most of our knowledge of this disease stems from epidemiologic studies, clinical experience, and studies
 using animal models that do not directly represent the disease in premature infants. An immature intestine that is colonized
 by bacteria is a prerequisite for the pathogenesis of NEC. Although causative microbes have not been found, newly developed
 analytic techniques now allow the detection of noncultivatable microbes and the determination of their overall diversity and
 metabolic capabilities. The National Institutes of Health Human Microbiome Road-map Project is likely to generate new information
 highly germane to und...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886726</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:30 +0100</pubDate>
            <guid isPermaLink="false">1886726</guid>        </item>
        <item>
            <title>What is the evidence for the use of probiotics in functional disorders?</title>
            <link>http://www.medworm.com/index.php?rid=1886725&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw4h8m1540230q67m%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A rationale for the use of probiotics for a number of functional gastrointestinal symptoms and syndromes can be developed,
 and an experimental basis for their use continues to emerge, but data from well-conducted clinical trials of probiotics in
 this area remain scarce. Irritable bowel syndrome (IBS) has attracted the most attention; recent revelations regarding the
 potential pathogenic roles of the enteric flora and immune activation have led to reawakened interest in bacteriotherapy for
 this common and challenging disorder. Some recent randomized, controlled studies attest to the efficacy of some probiotics
 in alleviating individual IBS symptoms, and selected strains have a more global impact. Evidence for long-term efficacy is
 also beginning to emerge, though m...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886725</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:30 +0100</pubDate>
            <guid isPermaLink="false">1886725</guid>        </item>
        <item>
            <title>Is irritable bowel syndrome an inflammatory disorder?</title>
            <link>http://www.medworm.com/index.php?rid=1886724&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe646247115l14060%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Histopathologic data demonstrate low-grade mucosal inflammation in a subset of patients with irritable bowel syndrome (IBS).
 This inflammatory infiltrate is mainly represented by increased numbers of T lymphocytes and mast cells lying in the lamina
 propria. The close apposition of immunocytes to gut nerves supplying the mucosa provides a basis for neuroimmune cross-talk,
 which may explain gut sensorimotor dysfunction and related symptoms in patients with IBS. A previous gastroenteritis (due
 to Campylobacter jejuni, Salmonella, Shigella, Escherichia coli, and, likely, viruses) is now an established etiologic factor for IBS (hence, postinfectious IBS). Other putative causes, such as undiagnosed food allergies, genetic abnormalities, stress, or bile acid malabsorption,...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886724</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:30 +0100</pubDate>
            <guid isPermaLink="false">1886724</guid>        </item>
        <item>
            <title>Clinical trials report</title>
            <link>http://www.medworm.com/index.php?rid=1886723&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn1774w2536k6r781%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11894-008-0074-zAuthors
		Walter J. Coyle
	

	
		Journal Current Gastroenterology ReportsOnline ISSN 1534-312XPrint ISSN 1522-8037
	
		Journal Volume Volume 10
	
		Journal Issue Volume 10, Number 4 / August, 2008 (Source: Current Gastroenterology Reports)</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886723</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:30 +0100</pubDate>
            <guid isPermaLink="false">1886723</guid>        </item>
        <item>
            <title>Significance of serrated polyps of the colon</title>
            <link>http://www.medworm.com/index.php?rid=1886731&amp;cid=s_35933_17_f&amp;fid=35933&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa1356q728623u642%2F</link>
            <description>This article describes the history of the serrated adenoma (both
 the traditional serrated adenoma and the sessile serrated adenoma) as well as the histology and endoscopic appearance of these
 lesions in comparison with hyperplastic polyps and mixed polyps. Although the exact pathway is the subject of ongoing research,
 compelling histologic associations and molecular phenotypes that define the model of the serrated polyp-carcinoma sequence,
 including microsatellite instability, BRAF/KRAS mutations, and CpG island methylator phenotype, provide strong evidence that this is a genuine pathway. Management of serrated
 neoplasia of the colon includes careful colonoscopy, complete removal of colonic polyps, sampling fields of diminutive polyps
 of the rectosigmoid, and basing surveillance on h...</description>
            <author>Current Gastroenterology Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1886731</comments>
            <pubDate>Thu, 16 Oct 2008 09:59:29 +0100</pubDate>
            <guid isPermaLink="false">1886731</guid>        </item>
    </channel>
</rss>
